PSMA-targeted low-molecular double conjugates for diagnostics and therapy
This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane anti...
Saved in:
| Published in | European journal of medicinal chemistry Vol. 225; p. 113752 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
France
Elsevier Masson SAS
05.12.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane antigen (PSMA); the comparison of high and low molecular weight PSMA-targeted conjugates was made. The considered conjugates were divided in the review into two main classes: diagnostic bimodal conjugates (which are containing two fragments for different types of diagnostics), theranostic conjugates (containing both therapeutic and diagnostic agents); also bimodal high molecular weight therapeutic conjugates containing two therapeutic agents are briefly discussed. The data of in vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 have been analyzed.
[Display omitted]
•50 LMW PSMA-targeted bimodal diagnostic or theranostic conjugates are described.•These conjugates are available, have high tissue penetration and fast pharmacokinetic.•Synthesis with Lys-like amino acids as a branch point is preferable for such conjugates.•Different radio and fluorescent label dosages at diagnostic conjugates is the problem.•Double diagnostic conjugates are most advanced for implementation in medicine. |
|---|---|
| AbstractList | This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane antigen (PSMA); the comparison of high and low molecular weight PSMA-targeted conjugates was made. The considered conjugates were divided in the review into two main classes: diagnostic bimodal conjugates (which are containing two fragments for different types of diagnostics), theranostic conjugates (containing both therapeutic and diagnostic agents); also bimodal high molecular weight therapeutic conjugates containing two therapeutic agents are briefly discussed. The data of in vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 have been analyzed.This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane antigen (PSMA); the comparison of high and low molecular weight PSMA-targeted conjugates was made. The considered conjugates were divided in the review into two main classes: diagnostic bimodal conjugates (which are containing two fragments for different types of diagnostics), theranostic conjugates (containing both therapeutic and diagnostic agents); also bimodal high molecular weight therapeutic conjugates containing two therapeutic agents are briefly discussed. The data of in vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 have been analyzed. This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane antigen (PSMA); the comparison of high and low molecular weight PSMA-targeted conjugates was made. The considered conjugates were divided in the review into two main classes: diagnostic bimodal conjugates (which are containing two fragments for different types of diagnostics), theranostic conjugates (containing both therapeutic and diagnostic agents); also bimodal high molecular weight therapeutic conjugates containing two therapeutic agents are briefly discussed. The data of in vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 have been analyzed. [Display omitted] •50 LMW PSMA-targeted bimodal diagnostic or theranostic conjugates are described.•These conjugates are available, have high tissue penetration and fast pharmacokinetic.•Synthesis with Lys-like amino acids as a branch point is preferable for such conjugates.•Different radio and fluorescent label dosages at diagnostic conjugates is the problem.•Double diagnostic conjugates are most advanced for implementation in medicine. This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane antigen (PSMA); the comparison of high and low molecular weight PSMA-targeted conjugates was made. The considered conjugates were divided in the review into two main classes: diagnostic bimodal conjugates (which are containing two fragments for different types of diagnostics), theranostic conjugates (containing both therapeutic and diagnostic agents); also bimodal high molecular weight therapeutic conjugates containing two therapeutic agents are briefly discussed. The data of in vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 have been analyzed. |
| ArticleNumber | 113752 |
| Author | Petrov, Stanislav A. Majouga, Alexander G. Machulkin, Aleksei E. Zyk, Nikolay Y. Beloglazkina, Elena K. |
| Author_xml | – sequence: 1 givenname: Stanislav A. surname: Petrov fullname: Petrov, Stanislav A. organization: Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia – sequence: 2 givenname: Nikolay Y. surname: Zyk fullname: Zyk, Nikolay Y. organization: Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia – sequence: 3 givenname: Aleksei E. orcidid: 0000-0001-7975-0346 surname: Machulkin fullname: Machulkin, Aleksei E. email: alekseymachulkin@rambler.ru organization: Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia – sequence: 4 givenname: Elena K. surname: Beloglazkina fullname: Beloglazkina, Elena K. organization: Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia – sequence: 5 givenname: Alexander G. surname: Majouga fullname: Majouga, Alexander G. organization: Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34464875$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkE1L7DAUhoMoOn78A7l0eTcdkzQfUxcXZPALFAV1HdLkdExpmzFJFf-9Haou7kJXBw7P-8L77KPt3veA0DHBc4KJOGnm0HRgnucUUzInpJCcbqEZkWKRF5SzbTTDlBY5pwXbQ_sxNhhjLjDeRXsFY4ItJJ-h6_uH27M86bCCBDZr_Vve-RbM0OqQWT9ULWTG982w0gliVvvx6_Sq9zE5EzPd2yw9Q9Dr90O0U-s2wtHnPUBPF-ePy6v85u7yenl2k5tC0JTXVBbANTdWMCK4tLwsOQYuWE0Z2BJLoLwyWkpccWppWYvKamNrXJfjAFkcoL9T7zr4lwFiUp2LBtpW9-CHqCgXC8oxoRv0zyc6VB1YtQ6u0-Fdfc0fATYBJvgYA9TfCMFqY1k1arKsNpbVZHmMnf4XMy7p5Hyfgnbtb-F_UxhGSa8OgorGQW_AugAmKevdzwUfN3KZdg |
| CitedBy_id | crossref_primary_10_1080_17425247_2022_2093856 crossref_primary_10_1016_j_ejmech_2023_115659 crossref_primary_10_3390_molecules27092617 crossref_primary_10_3390_molecules27103062 crossref_primary_10_3390_ph17111483 crossref_primary_10_3390_ijms241612637 crossref_primary_10_1089_cbr_2024_0066 crossref_primary_10_1134_S1070428024080013 crossref_primary_10_3390_molecules29246062 crossref_primary_10_31857_S0514749224020058 crossref_primary_10_3390_ijms23031158 crossref_primary_10_3390_ijms241411327 |
| Cites_doi | 10.1158/1078-0432.CCR-15-0503 10.2174/1568026611313080008 10.3322/caac.21492 10.1021/jm300488m 10.1002/anie.201310709 10.1016/j.neuroscience.2006.10.022 10.1016/j.bmcl.2009.10.061 10.1016/j.humpath.2009.06.003 10.2967/jnumed.119.234922 10.1002/anie.200602251 10.1038/natrevmats.2016.14 10.1186/s41181-021-00124-1 10.1002/anie.200600795 10.1053/j.semnuclmed.2017.05.007 10.1021/acs.chemrev.7b00013 10.1016/j.jphotobiol.2016.12.018 10.1002/pros.22784 10.1158/1078-0432.CCR-11-1357 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S 10.1002/cncr.28509 10.1021/jm051019l 10.1039/C6CC09781B 10.1002/ddr.21758 10.1093/jnci/djj070 10.1042/BJ20150942 10.1016/j.bmcl.2011.06.107 10.2967/jnumed.106.036020 10.1016/j.bmcl.2014.03.066 10.1016/j.urology.2019.04.004 10.1007/s00259-016-3372-y 10.1016/j.scib.2019.12.024 10.1126/scitranslmed.3003651 10.7150/thno.23335 10.1073/pnas.0502101102 10.1073/pnas.0610298104 10.7150/thno.36739 10.3390/molecules25245784 10.1021/bc200151q 10.1021/acs.jmedchem.5b01268 10.1021/acschembio.9b00160 10.2967/jnumed.118.219824 10.1002/advs.201802070 10.1155/2014/454503 10.1016/j.bmc.2004.06.031 10.1021/acs.jmedchem.0c01785 10.1056/NEJMoa1002965 10.1186/s13550-015-0104-4 10.3390/molecules22040523 10.7150/thno.13348 10.1039/b809537j 10.1021/acs.chemrev.8b00294 10.1016/j.nucmedbio.2014.01.001 10.3390/ph12010018 10.1021/acs.chemrev.8b00281 10.1021/bc200279b 10.2967/jnumed.114.147413 10.3390/biom9090421 10.1186/s13550-020-00740-z 10.2967/jnumed.118.213488 10.1111/bju.13540 10.1016/S0006-3495(99)76911-0 10.1016/j.molmed.2020.12.006 10.3389/fbioe.2019.00197 10.3762/bjoc.14.244 10.7150/thno.14860 10.2967/jnumed.116.178939 10.1038/modpathol.2011.112 10.1093/clinchem/35.5.755 10.1016/j.addr.2010.09.011 10.1148/radiol.2463070962 10.1021/jm000406m 10.1021/acsnano.9b08133 10.1002/ajoc.201900329 10.1158/0008-5472.CAN-10-1584 10.7150/thno.15344 10.2967/jnumed.117.201293 10.3390/ph13080173 10.3109/1061186X.2016.1154564 10.1158/0008-5472.CAN-09-1682 10.1002/smll.201900631 10.1016/j.jconrel.2021.01.010 10.1016/j.bmcl.2019.126894 10.1007/s00259-017-3922-y 10.1177/1536012118776068 10.1002/pros.22789 10.1021/acs.bioconjchem.8b00636 10.2967/jnumed.115.158550 10.1021/acs.bioconjchem.9b00252 10.1038/onc.2013.497 10.1007/s11307-014-0747-y 10.2967/jnumed.114.149526 10.1002/jlcr.3884 10.1021/acs.jmedchem.5b01210 10.1016/j.urology.2007.03.025 10.1016/j.eururo.2016.06.021 10.1016/j.addr.2019.06.007 10.1016/j.ejmech.2016.04.033 10.3389/fphar.2019.01436 10.3390/pharmaceutics12070614 10.1021/acs.bioconjchem.5b00679 10.1158/1535-7163.MCT-15-0722 10.2967/jnumed.116.186775 10.1007/s40336-017-0235-x 10.1038/s41391-018-0055-8 10.2967/jnumed.117.191395 10.1016/j.bmcl.2018.01.047 10.1021/jm401703a 10.1021/bc4005377 10.1080/2162402X.2019.1659095 10.1016/j.eururo.2016.08.002 10.1016/j.biomaterials.2010.02.030 10.1021/jm020515w 10.1002/jbm.b.34208 10.1158/1535-7163.MCT-14-0422 10.2967/jnumed.119.232330 10.2967/jnumed.118.212720 10.2967/jnumed.120.252114 10.1021/acs.bioconjchem.5b00687 10.1158/1535-7163.597.3.5 10.3390/ijms17040561 10.1021/acs.jmedchem.5b00457 10.1097/MNM.0000000000000966 10.1016/j.ijpharm.2016.08.048 10.7150/thno.40482 10.1002/med.21508 10.2967/jnumed.119.233064 10.1016/j.nano.2018.04.011 10.2967/jnumed.116.186767 10.1002/anie.201102872 10.1016/j.ymeth.2017.06.026 10.2967/jnumed.116.181768 10.1016/j.bbrc.2009.10.017 10.1021/acs.bioconjchem.9b00758 10.1186/2191-219X-3-36 10.1021/bc2002715 10.2214/AJR.16.16181 10.1053/j.semnuclmed.2019.02.008 10.5603/NMR.2016.0019 10.1002/cbic.201900632 10.1007/s10967-019-06800-6 10.1186/2191-219X-2-23 10.3390/pharmaceutics11070358 10.5858/arpa.2010-0740-OA 10.1016/j.mvr.2006.03.004 10.1007/s10967-017-5555-9 10.1021/acs.jmedchem.8b00240 10.1016/j.eururo.2016.08.003 10.1021/bc3003919 10.1021/acs.bioconjchem.6b00222 10.1021/acs.jmedchem.0c00291 10.1021/jm800765e 10.3390/cancers12061367 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier Masson SAS Copyright © 2021 Elsevier Masson SAS. All rights reserved. |
| Copyright_xml | – notice: 2021 Elsevier Masson SAS – notice: Copyright © 2021 Elsevier Masson SAS. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ejmech.2021.113752 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1768-3254 |
| ExternalDocumentID | 34464875 10_1016_j_ejmech_2021_113752 S0223523421006012 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .~1 0R~ 1RT 1~. 1~5 4.4 457 4G. 5GY 5VS 7-5 71M 8P~ 9JM 9JN AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARLI AATCM AAXUO ABFRF ABGSF ABJNI ABMAC ABOCM ABUDA ABYKQ ABZDS ACDAQ ACGFO ACIUM ACRLP ADBBV ADECG ADEZE ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AFZHZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJSZI ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC CS3 DOVZS DU5 EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FLBIZ FNPLU FYGXN G-Q GBLVA J1W KOM M2Y M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SES SPC SPCBC SSK SSP SSU SSZ T5K ~G- 1B1 29G 53G AAQXK AATTM AAXKI AAYOK AAYWO AAYXX ABFNM ABWVN ABXDB ACNNM ACRPL ACVFH ADCNI ADMUD ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRDE AGRNS AHHHB AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN BNPGV CITATION EJD FEDTE FGOYB G-2 HMS HMT HVGLF HZ~ IHE R2- RIG SCB SEW SOC SPT SSH WUQ CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c362t-f273e5a5cd641657d59950e564f24ed907e25bca770b52d29f6bdacdf0f900073 |
| IEDL.DBID | .~1 |
| ISSN | 0223-5234 1768-3254 |
| IngestDate | Thu Jul 10 23:57:58 EDT 2025 Wed Feb 19 02:28:34 EST 2025 Thu Apr 24 23:03:08 EDT 2025 Tue Jul 01 04:03:56 EDT 2025 Fri Feb 23 02:39:28 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Anticancer drugs PSMA Double conjugates Cancer diagnosis Targeted delivery Prostate cancer |
| Language | English |
| License | Copyright © 2021 Elsevier Masson SAS. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c362t-f273e5a5cd641657d59950e564f24ed907e25bca770b52d29f6bdacdf0f900073 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-7975-0346 |
| PMID | 34464875 |
| PQID | 2568250127 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2568250127 pubmed_primary_34464875 crossref_primary_10_1016_j_ejmech_2021_113752 crossref_citationtrail_10_1016_j_ejmech_2021_113752 elsevier_sciencedirect_doi_10_1016_j_ejmech_2021_113752 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-05 |
| PublicationDateYYYYMMDD | 2021-12-05 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | European journal of medicinal chemistry |
| PublicationTitleAlternate | Eur J Med Chem |
| PublicationYear | 2021 |
| Publisher | Elsevier Masson SAS |
| Publisher_xml | – name: Elsevier Masson SAS |
| References | Davis, Bennett, Thomas, Bjorkman (bib27) 2005; 102 Perera, Papa, Christidis, Wetherell, Hofman, Murphy, Bolton, Lawrentschuk (bib45) 2016; 70 Baccala, Sercia, Li, Heston, Zhou (bib15) 2007; 70 An, Chan, Kommidi, Ting (bib136) 2016; 207 Hensbergen, Van Willigen, Van Beurden, Van Leeuwen, Buckle, Schottelius, Maurer, Wester, Van Leeuwen (bib137) 2020; 31 Cardinale, Schäfer, Benešová, Bauder-Wüst, Leotta, Eder, Neels, Haberkorn, Giesel, Kopka (bib162) 2017; 58 Felber, Valentin, Wester (bib165) 2021; 6 Pei, Chen, Huang, Wang, Feng, Xu, Chen, Song, Jiang, Gu, Zhang, Gao, Chen (bib73) 2019; 15 Kommidi, Guo, Nurili, Vedvyas, Jin, McClure, Ehdaie, Sayman, Akin, Aras, Ting (bib131) 2018; 61 Chen, Dhara, Banerjee, Byun, Pullambhatla, Mease, Pomper (bib42) 2009; 390 Huang, Wang, Zhang, Doke, Difilippo, Heston (bib40) 2014; 74 Zamboglou, Schiller, Fechter, Wieser, Jilg, Chirindel, Salman, Drendel, Werner, Mix, Meyer, Grosu (bib44) 2016; 6 Abouzayed, Yim, Mitran, Rinne, Tolmachev, Larhed, Rosenström, Orlova (bib105) 2019; 11 Stemler, Hoffmann, Hierlmeier, Maus, Krause, Ezziddin, Jung, Bartholomä (bib118) 2021 Younes, Bartlett, Leonard, Kennedy, Lynch, Sievers, Forero-Torres (bib83) 2010; 363 Baranski, Schäfer, Bauder-Wüst, Roscher, Schmidt, Stenau, Simpfendörfer, Teber, Maier-Hein, Hadaschik, Haberkorn, Eder, Kopka (bib127) 2018; 59 Vargas, Ghosh, Azhdarinia (bib134) 2019; 60 Mease, Foss, Pomper (bib77) 2013; 13 Haffner, Kronberger, Ross, Sheehan, Zitt, Mühlmann, Öfner, Zelger, Ensinger, Yang, Geley, Margreiter, Bander (bib16) 2009; 40 McBride, Sharkey, Goldenberg (bib178) 2013; 3 Kozikowski, Nan, Conti, Zhang, Ramadan, Bzdega, Wroblewska, Neale, Pshenichkin, Wroblewski (bib35) 2001; 44 Lütje, Heskamp, Cornelissen, Poeppel, van den Broek, Rosenbaum-Krumme, Bockisch, Gotthardt, Rijpkema, Boerman (bib79) 2015; 5 Nomura, Pastorino, Jiang, Lambert, Crawford, Gymnopoulos, Piccioni, Juarez, Pingle, Makale, Kesari (bib18) 2014; 14 Anilkumar, Rajasekaran, Wang, Hankinson, Bander, Rajasekaran (bib26) 2003; 63 Kim, Kim, Kim (bib142) 2021; 64 Kopka, Benešová, Bařinka, Haberkorn, Babich (bib80) 2017; 58 Harmatys, Overchuk, Chen, Ding, Chen, Pomper, Zheng (bib120) 2018; 29 Goodman, Barwe, Ritter, McPherson, Vasko, Keen, Nanus, Bander, Rajasekaran (bib24) 2007; 31 Weineisen, Schottelius, Simecek, Baum, Yildiz, Beykan, Kulkarni, Lassmann, Klette, Eiber, Schwaiger, Wester (bib54) 2015; 56 Nakajima, Mitsunaga, Bander, Heston, Choyke, Kobayashi (bib124) 2011; 22 Benešová, Bauder-Wüst, Schäfer, Klika, Mier, Haberkorn, Kopka, Eder (bib41) 2016; 59 Pluen, Netti, Jain, Berk (bib87) 1999; 77 Maung, Mallari, Girtsman, Wu, Rowley, Santiago, Brunelle, Berkman (bib30) 2004; 12 Watanabe, Hanaoka, Sato, Nagaya, Harada, Mitsunaga, Kim, Paik, Wu, Choyke, Kobayashi (bib70) 2015; 56 Derks, Löwik, Sedelaar, Gotthardt, Boerman, Rijpkema, Lütje, Heskamp (bib69) 2019; 9 Guo, Kommidi, Vedvyas, McCloskey, Zhang, Chen, Nurili, Wu, Sayman, Akin, Rodriguez, Aras, Jin, Ting (bib133) 2019; 14 Anilkumar, Barwe, Christiansen, Rajasekaran, Kohn, Rajasekaran (bib25) 2006; 72 Bray, Ferlay, Soerjomataram, Siegel, Torre, Jemal (bib2) 2018; 68 Hrkach, Von Hoff, Ali, Andrianova, Auer, Campbell, De Witt, Figa, Figueiredo, Horhota, Low, McDonnell, Peeke, Retnarajan, Sabnis, Schnipper, Song, Song, Summa, Tompsett, Troiano, Hoven, Wright, LoRusso, Kantoff, Bander, Sweeney, Farokhzad, Langer, Zale (bib78) 2012; 4 Schottelius, Wurzer, Wissmiller, Beck, Koch, Gorpas, Notni, Buckle, Van Oosterom, Steiger, Ntziachristos, Schwaiger, Van Leeuwen, Wester (bib130) 2019; 60 Judmann, Braun, Wängler, Schirrmacher, Fricker, Wängler (bib95) 2020; 13 Majer, Jackson, Delahanty, Grella, Sen Ko, Li, Liu, Maclin, Poláková, Shaffer, Stoermer, Vitharana, Yanjun Wang, Zakrzewski, Rojas, Slusher, Wozniak, Burak, Limsakun, Tsukamoto (bib31) 2003; 46 Casi, Neri (bib91) 2015; 58 Lütje, Rijpkema, Helfrich, Oyen, Boerman (bib144) 2014; 16 Jackson, Scott, Thompson (bib150) 2017; 47 Mitran, Varasteh, Abouzayed, Rinne, Puuvuori (bib103) 2019 Simberg, Duza, Park, Essler, Pilch, Zhang, Derfus, Yang, Hoffman, Bhatia, Sailor, Ruoslahti (bib52) 2007; 104 Schäfer, Bauder-Wüst, Leotta, Zoller, Mier, Haberkorn, Eisenhut, Eder (bib101) 2012; 2 V Popik, Jiang, Li (bib113) 2019; 30 Waller, Ward, Mahan, Wismatt (bib82) 1989; 35 Tönnesmann, Meyer, Eder, Baranski (bib166) 2019; 12 Deberle, Benešová, Umbricht, Borgna, Büchler, Zhernosekov, Schibli, Müller (bib53) 2020; 10 Li, Zhan, Chen, Jha, Chen (bib171) 2019; 10 Yang, Mease, Pullambhatla, Lisok, Chen, Foss, Wang, Shallal, Edelman, Hoye, Attardo, Nimmagadda, Pomper (bib37) 2016; 59 Wang, Tsui, Ramamurthy, Zhang, Meyers, Kenney, Kiechle, Ponsky, Basilion (bib119) 2016; 15 Sengupta, Krishnan, Dudhe, Reddy, Giri, Chattopadhyay, Chelvam (bib126) 2018; 14 Pandit-Taskar, O'Donoghue, Divgi, Wills, Schwartz, Gönen, Smith-Jones, Bander, Scher, Larson, Morris (bib20) 2015; 5 Kostelnik, Orvig (bib148) 2019; 119 Tolvanen, Kalliokoski, Malaspina, Kuisma, Lahdenpohja, Postema, Miller, Scheinin (bib164) 2021; 62 Maurer, Graefen, van der Poel, Hamdy, Briganti, Eiber, Wester, van Leeuwen (bib122) 2020; 61 Šácha, Zámečník, Bařinka, Hlouchová, Vícha, Mlčochová, Hilgert, Eckschlager, Konvalinka (bib23) 2007; 144 Wüstemann, Haberkorn, Babich, Mier (bib7) 2019; 39 Samplaski, Heston, Elson, Magi-Galluzzi, Hansel (bib19) 2011; 24 Vahidfar, Fallahpoor, Farzanehfar, Divband, Ahmadzadehfar (bib63) 2019; 322 Noor, Van Zuylekom, Rudd, Waldeck, Roselt, Haskali, Wheatcroft, Yan, Hicks, Cullinane, Donnelly (bib99) 2020; 63 Bandari, Jiang, Reynolds, Bernskoetter, Szczodroski, Bassuner, Kirkpatrick, Rold, Sieckman, Hoffman, Connors, Smith (bib106) 2014; 41 Hensbergen, Buckle, van Willigen, Schottelius, Welling, van der Wijk, Maurer, van der Poel, van der Pluijm, van Weerden, Wester, van Leeuwen (bib129) 2020; 61 Derks, Rijpkema, V Amatdjais-groenen, Kip, Gerben, Sedelaar, Somford, Simons, Laverman (bib132) 2021 Wurzer, Parzinger, Konrad, Beck, Günther, Felber, Färber, Di Carlo, Wester (bib163) 2020; 10 Shallal, Minn, Banerjee, Lisok, Mease, Pomper (bib114) 2014; 25 Eiber, Fendler, Rowe, Calais, Hofman, Maurer, Schwarzenboeck, Kratowchil, Herrmann, Giesel (bib123) 2017; 58 Boros, Packard (bib147) 2019; 119 Escudero-Castellanos, Ocampo-García, Ferro-Flores, Santos-Cuevas, Morales-Ávila, Luna-Gutiérrez, Isaac-Olivé (bib110) 2019; 40 Majer, Hin, Stoermer, Adams, Xu, Duvall, Delahanty, Liu, Stathis, Wozniak, Slusher, Tsukamoto (bib32) 2006; 49 Sevick-Muraca, Sharma, Rasmussen, V Marshall, Wendt, Pham, Bonefas, Houston, Adams, Blanchard, Fisher, Elledge (bib156) 2008; 246 Kratochwil, Bruchertseifer, Rathke, Bronzel, Apostolidis, Weichert, Haberkorn, Giesel, Morgenstern (bib167) 2017; 58 Kim, Jung, Choi, Yang, Suh, Huh, Kim, Haam (bib169) 2010; 31 Son, Kwon, Ahn, Nam, Kim, Nam, Choi, Ha, Minn, Byun (bib48) 2020; 30 Weinstein, Van Osdol (bib88) 1992; 52 Wagner, Langer (bib154) 2011; 63 Cornford, Bellmunt, Bolla, Briers, De Santis, Gross, Henry, Joniau, Lam, Mason, van der Poel, van der Kwast, Rouvière, Wiegel, Mottet (bib5) 2017; 71 Edwards, Noone, Mariotto, Simard, Boscoe, Henley, Jemal, Cho, Anderson, Kohler, Eheman, Ward (bib4) 2014; 120 Israeli, Powell, Fair, Heston (bib10) 1993; 53 Escudero-Castellanos, Ocampo-García, Ferro-Flores, Isaac-Olivé, Santos-Cuevas, Olmos-Ortiz, García-Quiroz, García-Becerra, Díaz (bib115) 2017; 314 Jackson, Tays, Maclin, Ko, Li, Vitharana, Tsukamoto, Stoermer, Lu, Wozniak, Slusher (bib29) 2001; 44 Gotthardt, Van Eerd-Vismale, Oyen, De Jong, Zhang, Rolleman, Maecke, Béhé, Boerman (bib153) 2007; 48 Dreher, Liu, Michelich, Dewhirst, Yuan, Chilkoti (bib86) 2006; 98 Pavlicek, Ptacek, Cerny, Byun, Skultetyova, Pomper, Lubkowski, Barinka (bib47) 2014; 24 Chen, Chatterjee, Lisok, Minn, Pullambhatla, Wharram, Wang, Jin, Bhujwalla, Nimmagadda, Mease, Pomper (bib121) 2017; 167 Kwon, Son, Byun (bib66) 2019; 8 Lepage, Kuo, Roxin, Huh, Zhang, Kandasamy, Merkens, Kumlin, Limoges, Zeisler, Lin, Bénard, Perrin (bib168) 2020; 21 Stoermer, Vitharana, Hin, Delahanty, Duvall, Ferraris, Grella, Hoover, Rojas, Shanholtz, Smith, Stathis, Wu, Wozniak, Slusher, Tsukamoto (bib33) 2012; 55 Roma-Rodrigues, Pombo, Raposo, Pedrosa, Fernandes, Baptista (bib72) 2019; 7 Liolios (bib97) 2019 Banerjee, Pullambhatla, Shallal, Lisok, Mease, Pomper (bib100) 2011 Horoszewicz, Kawinski, Murphy (bib9) 1987; 7 van Leeuwen, Emmett, Ho, Delprado, Ting, Nguyen, Stricker (bib46) 2017; 119 Dadwal, Kang, Song, Sun, Dai, Baidoo, Brechbiel, Chong (bib151) 2011; 21 Mottet, Bellmunt, Bolla, Briers, Cumberbatch, De Santis, Fossati, Gross, Henry, Joniau, Lam, Mason, Matveev, Moldovan, van den Bergh, Van den Broeck, van der Poel, van der Kwast, Rouvière, Schoots, Wiegel, Cornford (bib3) 2017; 71 Chen, Pullambhatla, Banerjee, Byun, Stathis, Rojas, Slusher, Mease, Pomper (bib140) 2012; 23 Bostwick, Pacelli, Blute, Roche, Murphy (bib12) 1998; 82 Ferraris, Majer, Ni, Slusher, Rais, Wu, Wozniak, Alt, Rojas, Slusher, Tsukamoto (bib34) 2014; 57 Chang, Reuter, Heston, Bander, Grauer, Gaudin (bib13) 1999; 59 Barinka, Byun, Dusich, Banerjee, Chen, Castanares, Kozikowski, Mease, Pomper, Lubkowski (bib36) 2008; 51 Silver, Pellicer, Fair, Heston, Cordon-Cardo (bib22) 1997; 3 Tan, Aguiar, Haaland, Lopes (bib58) 2018; 21 Arndt, Feldmann, Koristka, Schäfer, Bergmann, Mitwasi, Berndt, Bachmann, Kegler, Schmitz, Puentes-Cala, Soto, Ehninger, Pietzsch, Liolios, Wunderlich, Kotzerke, Kopka, Bachmann (bib111) 2019 Benesová, Schäfer, Bauder-Wüst, Afshar-Oromieh, Kratochwil, Mier, Haberkorn, Kopka, Eder (bib43) 2015; 56 Abrahamse, Hamblin (bib141) 2016; 473 Chen, Pullambhatla, Foss, Byun, Nimmagadda, Senthamizhchelvan, Sgouros, Mease, Pomper (bib161) 2011; 17 Kawakami, Nakayama (bib11) 1997; 57 Sokol, Nikolskaya, Yabbarov, Zenin, Faustova, Belov, Zhunina, Mollaev, Zabolotsky, Tereshchenko, Severin (bib59) 2019; 107 Aras, Demirdag, Kommidi, Guo, Pavlova, Aygun, Karayel, Pehlivanoglu, Yeyin, Kyprianou, Chen, Harmsen, Sonmezoglu, Lundon, Oklu, Ting, Tewari, Akin, Sayman (bib143) 2021 Schug, Schmitthenner (bib139) 2020 Patil, Shmeeda, Amitay, Ohana, Kumar, Gabizon (bib170) Wüstemann (10.1016/j.ejmech.2021.113752_bib7) 2019; 39 Vahidfar (10.1016/j.ejmech.2021.113752_bib63) 2019; 322 Lim (10.1016/j.ejmech.2021.113752_bib98) 2019; 9 Tan (10.1016/j.ejmech.2021.113752_bib58) 2018; 21 Banerjee (10.1016/j.ejmech.2021.113752_bib128) 2011; 50 Schirrmacher (10.1016/j.ejmech.2021.113752_bib176) 2006; 45 Lundmark (10.1016/j.ejmech.2021.113752_bib108) 2020; 12 Wagner (10.1016/j.ejmech.2021.113752_bib154) 2011; 63 Kwon (10.1016/j.ejmech.2021.113752_bib66) 2019; 8 Abouzayed (10.1016/j.ejmech.2021.113752_bib105) 2019; 11 Kawakami (10.1016/j.ejmech.2021.113752_bib11) 1997; 57 Pei (10.1016/j.ejmech.2021.113752_bib73) 2019; 15 Wang (10.1016/j.ejmech.2021.113752_bib55) 2014; 13 Baccala (10.1016/j.ejmech.2021.113752_bib15) 2007; 70 Wurzer (10.1016/j.ejmech.2021.113752_bib163) 2020; 10 Benesová (10.1016/j.ejmech.2021.113752_bib43) 2015; 56 Weinstein (10.1016/j.ejmech.2021.113752_bib88) 1992; 52 Drake (10.1016/j.ejmech.2021.113752_bib173) 2013; 33 Noor (10.1016/j.ejmech.2021.113752_bib99) 2020; 63 Liu (10.1016/j.ejmech.2021.113752_bib68) 1998; 58 Chen (10.1016/j.ejmech.2021.113752_bib161) 2011; 17 Goodman (10.1016/j.ejmech.2021.113752_bib24) 2007; 31 Lepage (10.1016/j.ejmech.2021.113752_bib168) 2020; 21 Derks (10.1016/j.ejmech.2021.113752_bib69) 2019; 9 Casi (10.1016/j.ejmech.2021.113752_bib91) 2015; 58 Dadwal (10.1016/j.ejmech.2021.113752_bib151) 2011; 21 Lupold (10.1016/j.ejmech.2021.113752_bib51) 2004; 3 Lu (10.1016/j.ejmech.2021.113752_bib85) 2016; 17 Hoffmann (10.1016/j.ejmech.2021.113752_bib135) 2019; 130 Tönnesmann (10.1016/j.ejmech.2021.113752_bib166) 2019; 12 Böhmer (10.1016/j.ejmech.2021.113752_bib96) 2021; 27 Lütje (10.1016/j.ejmech.2021.113752_bib117) 2017; 130 Jin (10.1016/j.ejmech.2021.113752_bib50) 2016; 513 Robu (10.1016/j.ejmech.2021.113752_bib145) 2017; 58 Kim (10.1016/j.ejmech.2021.113752_bib169) 2010; 31 Bagalkot (10.1016/j.ejmech.2021.113752_bib76) 2006; 45 Pluen (10.1016/j.ejmech.2021.113752_bib87) 1999; 77 Eiber (10.1016/j.ejmech.2021.113752_bib123) 2017; 58 Garai (10.1016/j.ejmech.2021.113752_bib146) 2016; 19 Gourni (10.1016/j.ejmech.2021.113752_bib65) 2017; 22 Petrov (10.1016/j.ejmech.2021.113752_bib159) 2020; 25 Wurzer (10.1016/j.ejmech.2021.113752_bib160) 2020; 61 Majer (10.1016/j.ejmech.2021.113752_bib31) 2003; 46 Willhelm (10.1016/j.ejmech.2021.113752_bib84) 2016; 1 Roma-Rodrigues (10.1016/j.ejmech.2021.113752_bib72) 2019; 7 Rohrer (10.1016/j.ejmech.2021.113752_bib90) 2012; 30 Harmatys (10.1016/j.ejmech.2021.113752_bib120) 2018; 29 Baranski (10.1016/j.ejmech.2021.113752_bib127) 2018; 59 Liolios (10.1016/j.ejmech.2021.113752_bib104) 2016; 27 Hrkach (10.1016/j.ejmech.2021.113752_bib78) 2012; 4 Maurer (10.1016/j.ejmech.2021.113752_bib122) 2020; 61 Schottelius (10.1016/j.ejmech.2021.113752_bib130) 2019; 60 Pavlicek (10.1016/j.ejmech.2021.113752_bib47) 2014; 24 Kozikowski (10.1016/j.ejmech.2021.113752_bib35) 2001; 44 Ray Banerjee (10.1016/j.ejmech.2021.113752_bib38) 2016; 27 Chen (10.1016/j.ejmech.2021.113752_bib121) 2017; 167 Davis (10.1016/j.ejmech.2021.113752_bib27) 2005; 102 Majer (10.1016/j.ejmech.2021.113752_bib32) 2006; 49 Boros (10.1016/j.ejmech.2021.113752_bib147) 2019; 119 Kwon (10.1016/j.ejmech.2021.113752_bib116) 2019; 8 Vargas (10.1016/j.ejmech.2021.113752_bib134) 2019; 60 Pandit-Taskar (10.1016/j.ejmech.2021.113752_bib20) 2015; 5 Lütje (10.1016/j.ejmech.2021.113752_bib79) 2015; 5 Šácha (10.1016/j.ejmech.2021.113752_bib23) 2007; 144 Benešová (10.1016/j.ejmech.2021.113752_bib41) 2016; 59 Nakajima (10.1016/j.ejmech.2021.113752_bib124) 2011; 22 Mease (10.1016/j.ejmech.2021.113752_bib77) 2013; 13 Eder (10.1016/j.ejmech.2021.113752_bib109) 2014; 74 Sengupta (10.1016/j.ejmech.2021.113752_bib126) 2018; 14 Hensbergen (10.1016/j.ejmech.2021.113752_bib129) 2020; 61 Rahbar (10.1016/j.ejmech.2021.113752_bib1) 2018; 17 Zhang (10.1016/j.ejmech.2021.113752_bib172) 2020; 65 Weineisen (10.1016/j.ejmech.2021.113752_bib54) 2015; 56 Jackson (10.1016/j.ejmech.2021.113752_bib150) 2017; 47 Perera (10.1016/j.ejmech.2021.113752_bib45) 2016; 70 Sonn (10.1016/j.ejmech.2021.113752_bib125) 2016; 22 Schug (10.1016/j.ejmech.2021.113752_bib139) 2020 Wong (10.1016/j.ejmech.2021.113752_bib93) 2020; 14 Sevick-Muraca (10.1016/j.ejmech.2021.113752_bib156) 2008; 246 Chen (10.1016/j.ejmech.2021.113752_bib74) 2019; 6 Kratochwil (10.1016/j.ejmech.2021.113752_bib167) 2017; 58 Edwards (10.1016/j.ejmech.2021.113752_bib4) 2014; 120 Horoszewicz (10.1016/j.ejmech.2021.113752_bib9) 1987; 7 Jackson (10.1016/j.ejmech.2021.113752_bib29) 2001; 44 McBride (10.1016/j.ejmech.2021.113752_bib178) 2013; 3 Stemler (10.1016/j.ejmech.2021.113752_bib118) 2021 Gambhir (10.1016/j.ejmech.2021.113752_bib157) 2019; 60 Kommidi (10.1016/j.ejmech.2021.113752_bib131) 2018; 61 Jones (10.1016/j.ejmech.2021.113752_bib62) 2020; 12 Tolvanen (10.1016/j.ejmech.2021.113752_bib164) 2021; 62 Kopka (10.1016/j.ejmech.2021.113752_bib80) 2017; 58 Hekman (10.1016/j.ejmech.2021.113752_bib152) 2018; 8 Wester (10.1016/j.ejmech.2021.113752_bib67) 2019; 49 Cardinale (10.1016/j.ejmech.2021.113752_bib162) 2017; 58 Patil (10.1016/j.ejmech.2021.113752_bib170) 2018; 14 Banerjee (10.1016/j.ejmech.2021.113752_bib100) Li (10.1016/j.ejmech.2021.113752_bib171) 2019; 10 Sokol (10.1016/j.ejmech.2021.113752_bib59) 2019; 107 Wang (10.1016/j.ejmech.2021.113752_bib119) 2016; 15 Garanger (10.1016/j.ejmech.2021.113752_bib138) 2008 Kumar (10.1016/j.ejmech.2021.113752_bib57) 2016; 27 Auf Dem Keller (10.1016/j.ejmech.2021.113752_bib177) 2010; 70 Liolios (10.1016/j.ejmech.2021.113752_bib97) Srinivasarao (10.1016/j.ejmech.2021.113752_bib81) 2017; 117 Peng (10.1016/j.ejmech.2021.113752_bib75) 2019; 143 Subedi (10.1016/j.ejmech.2021.113752_bib112) 2016; 118 KleinJan (10.1016/j.ejmech.2021.113752_bib155) 2016; 43 Stoermer (10.1016/j.ejmech.2021.113752_bib33) 2012; 55 Bao (10.1016/j.ejmech.2021.113752_bib56) 2017; 53 Kim (10.1016/j.ejmech.2021.113752_bib142) 2021; 64 Backhaus (10.1016/j.ejmech.2021.113752_bib21) 2018; 45 Kelkar (10.1016/j.ejmech.2021.113752_bib60) 2011; 22 Bandari (10.1016/j.ejmech.2021.113752_bib107) 2021; 64 Meilert (10.1016/j.ejmech.2021.113752_bib89) 2012; vol. 899 Barinka (10.1016/j.ejmech.2021.113752_bib36) 2008; 51 Gotthardt (10.1016/j.ejmech.2021.113752_bib153) 2007; 48 Opoku-Damoah (10.1016/j.ejmech.2021.113752_bib61) 2016; 6 Anilkumar (10.1016/j.ejmech.2021.113752_bib26) 2003; 63 Silver (10.1016/j.ejmech.2021.113752_bib22) 1997; 3 Maung (10.1016/j.ejmech.2021.113752_bib30) 2004; 12 Liu (10.1016/j.ejmech.2021.113752_bib14) 1997; 57 Schäfer (10.1016/j.ejmech.2021.113752_bib101) 2012; 2 Do Kwon (10.1016/j.ejmech.2021.113752_bib102) 2018; 28 Aras (10.1016/j.ejmech.2021.113752_bib143) 2021 Chen (10.1016/j.ejmech.2021.113752_bib42) 2009; 390 Mitran (10.1016/j.ejmech.2021.113752_bib103) Guo (10.1016/j.ejmech.2021.113752_bib133) 2019; 14 Ferraris (10.1016/j.ejmech.2021.113752_bib34) 2014; 57 Nomura (10.1016/j.ejmech.2021.113752_bib18) 2014; 14 Felber (10.1016/j.ejmech.2021.113752_bib165) 2021; 6 Abrahamse (10.1016/j.ejmech.2021.113752_bib141) 2016; 473 Lütje (10.1016/j.ejmech.2021.113752_bib144) 2014; 16 V Popik (10.1016/j.ejmech.2021.113752_bib113) 2019; 30 Waller (10.1016/j.ejmech.2021.113752_bib82) 1989; 35 Sun (10.1016/j.ejmech.2021.113752_bib6) 2020; 12 Simberg (10.1016/j.ejmech.2021.113752_bib52) 2007; 104 Yang (10.1016/j.ejmech.2021.113752_bib37) 2016; 59 Derks (10.1016/j.ejmech.2021.113752_bib132) Bostwick (10.1016/j.ejmech.2021.113752_bib12) 1998; 82 Chang (10.1016/j.ejmech.2021.113752_bib13) 1999; 59 Shen (10.1016/j.ejmech.2021.113752_bib49) 2013; 8 Benoiton (10.1016/j.ejmech.2021.113752_bib174) 2006 Kostelnik (10.1016/j.ejmech.2021.113752_bib148) 2019; 119 Haffner (10.1016/j.ejmech.2021.113752_bib16) 2009; 40 Judmann (10.1016/j.ejmech.2021.113752_bib95) 2020; 13 Sun (10.1016/j.ejmech.2021.113752_bib92) 2021; 333 Huang (10.1016/j.ejmech.2021.113752_bib40) 2014; 74 Bandari (10.1016/j.ejmech.2021.113752_bib106) 2014; 41 Watanabe (10.1016/j.ejmech.2021.113752_bib70) 2015; 56 Arndt (10.1016/j.ejmech.2021.113752_bib111) 2019 Shallal (10.1016/j.ejmech.2021.113752_bib114) 2014; 25 Eder (10.1016/j.ejmech.2021.113752_bib39) 2012; 23 Anilkumar (10.1016/j.ejmech.2021.113752_bib25) 2006; 72 Escudero-Castellanos (10.1016/j.ejmech.2021.113752_bib110) 2019; 40 Bernard-Gauthier (10.1016/j.ejmech.2021.113752_bib175) 2014; 2014 Wernicke (10.1016/j.ejmech.2021.113752_bib17) 2011; 135 Machulkin (10.1016/j.ejmech.2021.113752_bib28) 2016; 24 Samplaski (10.1016/j.ejmech.2021.113752_bib19) 2011; 24 Kunjiappan (10.1016/j.ejmech.2021.113752_bib64) 2021; 82 Younes (10.1016/j.ejmech.2021.113752_bib83) 2010; 363 Deberle (10.1016/j.ejmech.2021.113752_bib53) 2020; 10 Cornford (10.1016/j.ejmech.2021.113752_bib5) 2017; 71 Dreher (10.1016/j.ejmech.2021.113752_bib86) 2006; 98 Escudero-Castellanos (10.1016/j.ejmech.2021.113752_bib115) 2017; 314 Wang (10.1016/j.ejmech.2021.113752_bib8) 2010; 20 Krall (10.1016/j.ejmech.2021.113752_bib158) 2014; 53 Bugby (10.1016/j.ejmech.2021.113752_bib149) 2017; 5 Zamboglou (10.1016/j.ejmech.2021.113752_bib44) 2016; 6 van Leeuwen (10.1016/j.ejmech.2021.113752_bib46) 2017; 119 Chen (10.1016/j.ejmech.2021.113752_bib140) 2012; 23 Mottet (10.1016/j.ejmech.2021.113752_bib3) 2017; 71 Son (10.1016/j.ejmech.2021.113752_bib48) 2020; 30 Israeli (10.1016/j.ejmech.2021.113752_bib10) 1993; 53 Hillier (10.1016/j.ejmech.2021.113752_bib71) 2009; 69 Hensbergen (10.1016/j.ejmech.2021.113752_bib137) 2020; 31 Bray (10.1016/j.ejmech.2021.113752_bib2) 2018; 68 An (10.1016/j.ejmech.2021.113752_bib136) 2016; 207 |
| References_xml | – volume: 27 start-page: 1681 year: 2016 end-page: 1689 ident: bib57 article-title: Design of a small-molecule drug conjugate for prostate cancer targeted theranostics publication-title: Bioconjugate Chem. – start-page: 1 year: 2021 end-page: 12 ident: bib118 article-title: A structure-activity relationship study of bimodal BODIPY-labeled PSMA-targeting bioconjugates publication-title: ChemMedChem – volume: 65 start-page: 564 year: 2020 end-page: 572 ident: bib172 article-title: Janus γ-Fe2O3/SiO2-based nanotheranostics for dual-modal imaging and enhanced synergistic cancer starvation/chemodynamic therapy publication-title: Sci. Bull. – volume: 130 start-page: 1 year: 2019 end-page: 12 ident: bib135 article-title: The impact of 68Ga-PSMA PET/CT and PET/MRI on the management of prostate cancer publication-title: Urology – volume: 30 start-page: 126894 year: 2020 ident: bib48 article-title: Design and synthesis of a novel BODIPY-labeled PSMA inhibitor publication-title: Bioorg. Med. Chem. Lett – volume: 13 start-page: 1 year: 2020 end-page: 31 ident: bib95 article-title: Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy publication-title: Pharmaceuticals – volume: 23 start-page: 688 year: 2012 end-page: 697 ident: bib39 article-title: 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging publication-title: Bioconjugate Chem. – volume: 61 start-page: 4256 year: 2018 end-page: 4262 ident: bib131 article-title: 18F-Positron emitting/trimethine cyanine-fluorescent contrast for image-guided prostate cancer management publication-title: J. Med. Chem. – volume: 6 start-page: 986 year: 2016 end-page: 1003 ident: bib61 article-title: Versatile nanosystem-based cancer theranostics: design inspiration and predetermined routing publication-title: Theranostics – volume: 12 start-page: 4969 year: 2004 end-page: 4979 ident: bib30 article-title: Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates publication-title: Bioorg. Med. Chem. – volume: 63 start-page: 539 year: 2011 end-page: 546 ident: bib154 article-title: Approaches using molecular imaging technology - use of PET in clinical microdose studies publication-title: Adv. Drug Deliv. Rev. – volume: 135 start-page: 1486 year: 2011 end-page: 1489 ident: bib17 article-title: Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme publication-title: Arch. Pathol. Lab Med. – volume: 50 start-page: 9167 year: 2011 end-page: 9170 ident: bib128 article-title: Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen publication-title: Angew. Chem. Int. Ed. – volume: 61 start-page: 234 year: 2020 end-page: 241 ident: bib129 article-title: Hybrid tracers based on cyanine backbones targeting prostate-specific membrane antigen: tuning pharmacokinetic properties and exploring dye-protein interaction publication-title: J. Nucl. Med. – volume: 56 start-page: 1169 year: 2015 end-page: 1176 ident: bib54 article-title: 68 Ga- and 177 Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies publication-title: J. Nucl. Med. – volume: 14 start-page: 1 year: 2014 end-page: 9 ident: bib18 article-title: Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases publication-title: Canc. Cell Int. – volume: 3 start-page: 81 year: 1997 end-page: 85 ident: bib22 article-title: Prostate-specific membrane antigen expression in normal and malignant human tissues publication-title: Clin. Canc. Res. – volume: 118 start-page: 208 year: 2016 end-page: 218 ident: bib112 article-title: Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands publication-title: Eur. J. Med. Chem. – volume: 17 start-page: 1 year: 2018 end-page: 9 ident: bib1 article-title: PSMA theranostics: current status and future directions publication-title: Mol. Imag. – volume: 45 start-page: 6047 year: 2006 end-page: 6050 ident: bib176 article-title: 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor publication-title: Angew. Chem. Int. Ed. – volume: 19 start-page: 93 year: 2016 end-page: 98 ident: bib146 article-title: Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy publication-title: Nucl. Med. Rev. Cent. E Eur. – volume: 53 start-page: 227 year: 1993 end-page: 230 ident: bib10 article-title: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen publication-title: Canc. Res. – volume: 14 start-page: 2585 year: 2020 end-page: 2627 ident: bib93 article-title: Nanomaterials for nanotheranostics: tuning their properties according to disease needs publication-title: ACS Nano – volume: 13 start-page: 2595 year: 2014 end-page: 2606 ident: bib55 article-title: Development of targeted near-infrared imaging agents for prostate cancer publication-title: Mol. Canc. Therapeut. – volume: 29 start-page: 3746 year: 2018 end-page: 3756 ident: bib120 article-title: Tuning pharmacokinetics to improve tumor accumulation of a prostate-specific membrane antigen-targeted phototheranostic agent publication-title: Bioconjugate Chem. – volume: 246 start-page: 734 year: 2008 end-page: 741 ident: bib156 article-title: Imaging of lymph flow in breast cancer patients after microdose administration of a Methods : feasibility study publication-title: Radiology – volume: 17 start-page: 561 year: 2016 ident: bib85 article-title: Linkers having a crucial role in antibody–drug conjugates publication-title: Int. J. Mol. Sci. – volume: 45 start-page: 8149 year: 2006 end-page: 8152 ident: bib76 article-title: An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform publication-title: Angew. Chem. Int. Ed. – volume: 49 start-page: 2876 year: 2006 end-page: 2885 ident: bib32 article-title: Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1′ side chain publication-title: J. Med. Chem. – volume: 74 start-page: 702 year: 2014 end-page: 713 ident: bib40 article-title: Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker publication-title: Prostate – volume: 2 start-page: 1 year: 2012 end-page: 11 ident: bib101 article-title: A dimerized urea-based inhibitor of the prostatespecific membrane antigen for 68Ga-PET imaging of prostate cancer publication-title: EJNMMI Res. – volume: 35 start-page: 755 year: 1989 end-page: 765 ident: bib82 article-title: Current concepts in proteinuria publication-title: Clin. Chem. – volume: 48 start-page: 596 year: 2007 end-page: 601 ident: bib153 article-title: Indication for different mechanisms of kidney uptake of radiolabeled peptides publication-title: J. Nucl. Med. – volume: 70 start-page: 385 year: 2007 end-page: 390 ident: bib15 article-title: Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms publication-title: Urology – volume: 53 start-page: 1611 year: 2017 end-page: 1614 ident: bib56 article-title: PSMA-targeted contrast agents for intraoperative imaging of prostate cancer publication-title: Chem. Commun. – volume: 107 start-page: 1150 year: 2019 end-page: 1158 ident: bib59 article-title: Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells publication-title: J. Biomed. Mater. Res. B Appl. Biomater. – volume: 71 start-page: 618 year: 2017 end-page: 629 ident: bib3 article-title: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent publication-title: Eur. Urol. – volume: 30 start-page: 1314 year: 2019 end-page: 1322 ident: bib113 article-title: Development of bispecific NT-PSMA heterodimer for prostate cancer imaging: a potential approach to address tumor heterogeneity publication-title: Bioconjugate Chem. – volume: 12 start-page: 1 year: 2020 end-page: 15 ident: bib108 article-title: Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer—optimization of the affinity towards PSMA by linker modification in murine model publication-title: Pharmaceutics – volume: 40 start-page: 278 year: 2019 end-page: 286 ident: bib110 article-title: Synthesis and preclinical evaluation of the 177 Lu-DOTA-PSMA(inhibitor)-Lys 3 -bombesin heterodimer designed as a radiotheranostic probe for prostate cancer publication-title: Nucl. Med. Commun. – volume: 7 start-page: 927—935 year: 1987 ident: bib9 article-title: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients publication-title: Anticancer Res. – volume: 9 start-page: 421 year: 2019 ident: bib98 article-title: Tumor uptake of triazine dendrimers decorated with four, sixteen, and sixty-four PSMA-targeted ligands: passive versus active tumor targeting publication-title: Biomolecules – volume: 363 start-page: 1812 year: 2010 end-page: 1821 ident: bib83 article-title: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas publication-title: N. Engl. J. Med. – volume: 82 start-page: 309 year: 2021 end-page: 340 ident: bib64 article-title: Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: a state-of-the-art review publication-title: Drug Dev. Res. – volume: 9 start-page: 6824 year: 2019 end-page: 6839 ident: bib69 article-title: PSMA-targeting agents for radio- and fluorescenceguided prostate cancer surgery publication-title: Theranostics – volume: 59 start-page: 1761 year: 2016 end-page: 1775 ident: bib41 article-title: Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-Targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors publication-title: J. Med. Chem. – volume: 22 start-page: 1403 year: 2016 end-page: 1412 ident: bib125 article-title: Fluorescent image-guided surgery with an anti-Prostate Stem Cell Antigen (PSCA) diabody enables targeted resection of mouse prostate cancer xenografts in real time publication-title: Clin. Canc. Res. – volume: 11 start-page: 358 year: 2019 ident: bib105 article-title: Synthesis and preclinical evaluation of radio-iodinated GRPR/PSMA bispecific heterodimers for the theranostics application in prostate cancer publication-title: Pharmaceutics – volume: 207 start-page: 266 year: 2016 end-page: 273 ident: bib136 article-title: Dual PET and near-infrared fluorescence imaging probes as tools for imaging in oncology publication-title: Am. J. Roentgenol. – volume: 21 start-page: 943 year: 2020 end-page: 947 ident: bib168 article-title: Toward 18 F-labeled theranostics: a single agent that can Be labeled with 18 F, 64 Cu, or 177 Lu publication-title: Chembiochem – volume: 70 start-page: 926 year: 2016 end-page: 937 ident: bib45 article-title: Sensitivity, specificity, and predictors of positive 68Ga–Prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis publication-title: Eur. Urol. – volume: 58 start-page: 425 year: 2017 end-page: 431 ident: bib162 article-title: Preclinical evaluation of 18 F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging publication-title: J. Nucl. Med. – volume: 143 start-page: 37 year: 2019 end-page: 67 ident: bib75 article-title: Intratumoral fate of functional nanoparticles in response to microenvironment factor: implications on cancer diagnosis and therapy publication-title: Adv. Drug Deliv. Rev. – volume: 30 start-page: 76 year: 2012 end-page: 79 ident: bib90 article-title: Consideration for the safe and effective manufacturing of antibody drug conjugates publication-title: Chim. Oggi/Chemistry Today. – volume: 58 start-page: 67S year: 2017 end-page: 76S ident: bib123 article-title: Prostate-specific membrane antigen ligands for imaging and therapy publication-title: J. Nucl. Med. – volume: 25 start-page: 393 year: 2014 end-page: 405 ident: bib114 article-title: Heterobivalent agents targeting PSMA and integrin - αvβ3 publication-title: Bioconjugate Chem. – volume: 8 start-page: 1588 year: 2019 end-page: 1600 ident: bib66 article-title: Prostate-specific membrane antigen (PSMA)-Targeted radionuclide probes for imaging and therapy of prostate cancer publication-title: Asian J. Org. Chem. – volume: 24 start-page: 679 year: 2016 end-page: 693 ident: bib28 article-title: Small-molecule PSMA ligands. Current state, SAR and perspectives publication-title: J. Drug Target. – volume: 58 start-page: 235 year: 2017 end-page: 242 ident: bib145 article-title: Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer publication-title: J. Nucl. Med. – volume: 13 start-page: 951 year: 2013 end-page: 962 ident: bib77 article-title: PET imaging in prostate cancer: focus on prostate-specific membrane antigen publication-title: Curr. Top. Med. Chem. – volume: 49 start-page: 302 year: 2019 end-page: 312 ident: bib67 article-title: PSMA-targeted radiopharmaceuticals for imaging and therapy publication-title: Semin. Nucl. Med. – year: 2006 ident: bib174 article-title: Chemistry of Peptide Synthesis – volume: 6 start-page: 1619 year: 2016 end-page: 1628 ident: bib44 article-title: 68Ga-HBED-CC-PSMA PET/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison publication-title: Theranostics – volume: 119 start-page: 870 year: 2019 end-page: 901 ident: bib147 article-title: Radioactive transition metals for imaging and therapy publication-title: Chem. Rev. – volume: 322 start-page: 237 year: 2019 end-page: 248 ident: bib63 article-title: Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer publication-title: J. Radioanal. Nucl. Chem. – volume: 7 start-page: 1 year: 2019 end-page: 18 ident: bib72 article-title: Nanotheranostics targeting the tumor microenvironment publication-title: Front. Bioeng. Biotechnol. – volume: 39 start-page: 40 year: 2019 end-page: 69 ident: bib7 article-title: Targeting prostate cancer: prostate-specific membrane antigen based diagnosis and therapy publication-title: Med. Res. Rev. – volume: 16 start-page: 747 year: 2014 end-page: 755 ident: bib144 article-title: Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation publication-title: Mol. Imag. Biol. – volume: 33 start-page: 5053 year: 2013 end-page: 5064 ident: bib173 article-title: Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy publication-title: Oncogene – volume: 44 start-page: 4170 year: 2001 end-page: 4175 ident: bib29 article-title: Design and Pharmacological Activity of Phosphinic Acid Based NAALADase publication-title: Inhibitors – volume: 68 start-page: 394 year: 2018 end-page: 424 ident: bib2 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA. Canc. J. Clin. – volume: 10 start-page: 1678 year: 2020 end-page: 1693 ident: bib53 article-title: Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity publication-title: Theranostics – volume: 46 start-page: 1989 year: 2003 end-page: 1996 ident: bib31 article-title: Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor publication-title: J. Med. Chem. – volume: 14 start-page: 2665 year: 2018 end-page: 2679 ident: bib126 article-title: Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer publication-title: Beilstein J. Org. Chem. – volume: 77 start-page: 542 year: 1999 end-page: 552 ident: bib87 article-title: Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations publication-title: Biophys. J. – volume: 69 start-page: 6932 year: 2009 end-page: 6940 ident: bib71 article-title: Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer publication-title: Canc. Res. – volume: 14 start-page: 1449 year: 2019 end-page: 1459 ident: bib133 article-title: A fluorescent, [18F]-Positron-Emitting agent for imaging prostate-specific membrane antigen allows genetic reporting in adoptively transferred, genetically modified cells publication-title: ACS Chem. Biol. – volume: 52 start-page: 2747 year: 1992 end-page: 2752 ident: bib88 article-title: Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the “binding site barrier publication-title: Canc. Res. – volume: 45 start-page: 860 year: 2018 end-page: 877 ident: bib21 article-title: Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives publication-title: Eur. J. Nucl. Med. Mol. Imag. – volume: 60 start-page: 736 year: 2019 end-page: 744 ident: bib157 article-title: Proceedings: pathways for successful translation of new imaging agents and modalities—phase III studies publication-title: J. Nucl. Med. – year: 2019 ident: bib111 article-title: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR publication-title: OncoImmunology – volume: 22 start-page: 1879 year: 2011 end-page: 1903 ident: bib60 article-title: Theranostics: combining imaging and therapy publication-title: Bioconjugate Chem. – year: 2019 ident: bib97 article-title: Bispecific radioligands targeting prostate - specific membrane antigen and gastrin - releasing peptide receptors on the surface of prostate cancer cells – volume: 41 start-page: 355 year: 2014 end-page: 363 ident: bib106 article-title: Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer publication-title: Nucl. Med. Biol. – volume: 58 start-page: 17S year: 2017 end-page: 26S ident: bib80 article-title: Glu-ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers publication-title: J. Nucl. Med. – volume: 1 start-page: 16014 year: 2016 ident: bib84 article-title: Analysis of nanoparticle delivery to tumours publication-title: Nat. Rev. Mater. – volume: 21 start-page: 7513 year: 2011 end-page: 7515 ident: bib151 article-title: Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates publication-title: Bioorg. Med. Chem. Lett – volume: 130 start-page: 42 year: 2017 end-page: 50 ident: bib117 article-title: PSMA ligands in prostate cancer – probe optimization and theranostic applications publication-title: Methods – volume: 82 start-page: 2256 year: 1998 end-page: 2261 ident: bib12 article-title: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases publication-title: Cancer – year: 2020 ident: bib139 article-title: Modular Synthesis of Dual-And Tri-modal Targeted Molecular Imaging Agents – volume: 10 start-page: 1 year: 2019 end-page: 16 ident: bib171 article-title: Docetaxel and doxorubicin codelivery by nanocarriers for synergistic treatment of prostate cancer publication-title: Front. Pharmacol. – volume: 17 start-page: 7645 year: 2011 end-page: 7653 ident: bib161 article-title: 2-(3-{1-Carboxy-5-[(6-[ 18 F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic acid, [ 18 F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer publication-title: Clin. Canc. Res. – volume: 119 start-page: 209 year: 2017 end-page: 215 ident: bib46 article-title: Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer publication-title: BJU Int. – volume: 57 start-page: 3629 year: 1997 end-page: 3634 ident: bib14 article-title: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium publication-title: Canc. Res. – volume: 44 start-page: 298 year: 2001 end-page: 301 ident: bib35 article-title: Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) publication-title: J. Med. Chem. – volume: 71 start-page: 630 year: 2017 end-page: 642 ident: bib5 article-title: EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer publication-title: Eur. Urol. – volume: 20 start-page: 392 year: 2010 end-page: 397 ident: bib8 article-title: Bioisosterism of urea-based GCPII inhibitors: synthesis and structure–activity relationship studies publication-title: Bioorg. Med. Chem. Lett – volume: 144 start-page: 1361 year: 2007 end-page: 1372 ident: bib23 article-title: Expression of glutamate carboxypeptidase II in human brain publication-title: Neuroscience – year: 2021 ident: bib132 article-title: Theranostics Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer – volume: 62 start-page: 679 year: 2021 end-page: 684 ident: bib164 article-title: Safety, biodistribution, and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers publication-title: J. Nucl. Med. – volume: 31 start-page: 1199 year: 2007 end-page: 1203 ident: bib24 article-title: Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2 publication-title: Int. J. Oncol. – volume: 27 start-page: 379 year: 2021 end-page: 393 ident: bib96 article-title: Multivalent probes in molecular imaging: reality or future? publication-title: Trends Mol. Med. – volume: 10 year: 2020 ident: bib163 article-title: Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics publication-title: EJNMMI Res. – volume: 6 start-page: 1 year: 2021 end-page: 24 ident: bib165 article-title: Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors? publication-title: EJNMMI Radiopharm. Chem. – year: 2019 ident: bib103 article-title: Heterodimer for PET and SPECT Diagnostic Imaging – volume: 27 start-page: 737 year: 2016 end-page: 751 ident: bib104 article-title: Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer publication-title: Bioconjugate Chem. – volume: 51 start-page: 7737 year: 2008 end-page: 7743 ident: bib36 article-title: Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization publication-title: J. Med. Chem. – volume: 74 start-page: 659 year: 2014 end-page: 668 ident: bib109 article-title: Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer publication-title: Prostate – volume: 60 start-page: 71 year: 2019 end-page: 78 ident: bib130 article-title: Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer publication-title: J. Nucl. Med. – volume: 59 start-page: 3192 year: 1999 end-page: 3198 ident: bib13 article-title: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature publication-title: Canc. Res. – volume: 102 start-page: 5981 year: 2005 end-page: 5986 ident: bib27 article-title: Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 8 start-page: 1 year: 2013 end-page: 8 ident: bib49 article-title: Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA) publication-title: PloS One – volume: 22 start-page: 523 year: 2017 ident: bib65 article-title: Metal-based PSMA radioligands publication-title: Molecules – volume: 25 start-page: 5784 year: 2020 ident: bib159 article-title: Polypeptide-based molecular platform and its docetaxel/sulfo-cy5-containing conjugate for targeted delivery to prostate specific membrane antigen publication-title: Molecules – volume: 57 start-page: 243 year: 2014 end-page: 247 ident: bib34 article-title: δ-thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors publication-title: J. Med. Chem. – volume: 14 start-page: 1407 year: 2018 end-page: 1416 ident: bib170 article-title: Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA) publication-title: Nanomed. Nanotechnol. Biol. Med. – volume: 59 start-page: 206 year: 2016 end-page: 218 ident: bib37 article-title: Fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) publication-title: J. Med. Chem. – volume: 63 start-page: 9258 year: 2020 end-page: 9270 ident: bib99 article-title: Bivalent inhibitors of prostate-specific membrane antigen conjugated to desferrioxamine B squaramide labeled with zirconium-89 or gallium-68 for diagnostic imaging of prostate cancer publication-title: J. Med. Chem. – year: 2011 ident: bib100 article-title: A modular strategy to prepare multivalent inhibitors of prostate- specific membrane antigen ( PSMA ) – volume: 43 start-page: 1857 year: 2016 end-page: 1867 ident: bib155 article-title: Fluorescence guided surgery and tracer-dose, fact or fiction? publication-title: Eur. J. Nucl. Med. Mol. Imag. – volume: 3 start-page: 1 year: 2013 end-page: 11 ident: bib178 article-title: Radiofluorination using aluminum-fluoride (Al18F) publication-title: EJNMMI Res. – volume: 53 start-page: 4231 year: 2014 end-page: 4235 ident: bib158 article-title: A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors publication-title: Angew. Chem. Int. Ed. – volume: 55 start-page: 5922 year: 2012 end-page: 5932 ident: bib33 article-title: Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds publication-title: J. Med. Chem. – volume: 61 start-page: 6 year: 2020 end-page: 12 ident: bib122 article-title: Prostate-specific membrane antigen–guided surgery publication-title: J. Nucl. Med. – volume: 390 start-page: 624 year: 2009 end-page: 629 ident: bib42 article-title: A low molecular weight PSMA-based fluorescent imaging agent for cancer publication-title: Biochem. Biophys. Res. Commun. – volume: 6 start-page: 1802070 year: 2019 ident: bib74 article-title: Therapeutic remodeling of the tumor microenvironment enhances nanoparticle delivery publication-title: Adv. Sci. – volume: 12 start-page: 1 year: 2020 end-page: 14 ident: bib62 article-title: PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy publication-title: Cancers – volume: 58 start-page: 8751 year: 2015 end-page: 8761 ident: bib91 article-title: Antibody–drug conjugates and small molecule–drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents publication-title: J. Med. Chem. – start-page: 1 year: 2021 end-page: 12 ident: bib143 article-title: Small molecule, multimodal, [18F]-PET and fluorescence imaging agent targeting prostate-specific membrane antigen: first-in-human study publication-title: Clin. Genitourin. Canc. – volume: 8 start-page: 2161 year: 2018 end-page: 2170 ident: bib152 article-title: Tumor-targeted dual-modality imaging to improve intraoperative visualization of clear cell renal cell carcinoma: a first in man study publication-title: Theranostics – volume: 12 start-page: 10 year: 2020 end-page: 17 ident: bib6 article-title: Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer publication-title: Cureus – volume: 56 start-page: 914 year: 2015 end-page: 920 ident: bib43 article-title: Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer publication-title: J. Nucl. Med. – volume: 8 start-page: 1588 year: 2019 end-page: 1600 ident: bib116 article-title: Prostate-specific membrane antigen (PSMA)-Targeted radionuclide probes for imaging and therapy of prostate cancer publication-title: Asian J. Org. Chem. – volume: 24 start-page: 1521 year: 2011 end-page: 1529 ident: bib19 article-title: Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature publication-title: Mod. Pathol. – volume: 64 start-page: 2151 year: 2021 end-page: 2166 ident: bib107 article-title: Development of heterobivalent theranostic probes having high affinity/selectivity for the GRPR/PSMA publication-title: J. Med. Chem. – volume: 47 start-page: 493 year: 2017 end-page: 523 ident: bib150 article-title: Clinical applications of radiolabeled peptides for PET publication-title: Semin. Nucl. Med. – volume: 31 start-page: 375 year: 2020 end-page: 395 ident: bib137 article-title: Image-guided surgery: are we getting the most out of small-molecule prostate-specific-membrane-antigen-targeted tracers? publication-title: Bioconjugate Chem. – volume: 58 start-page: 1624 year: 2017 end-page: 1631 ident: bib167 article-title: Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding publication-title: J. Nucl. Med. – volume: 60 start-page: 459 year: 2019 end-page: 465 ident: bib134 article-title: New developments in dual-labeled molecular imaging agents publication-title: J. Nucl. Med. – volume: 31 start-page: 4592 year: 2010 end-page: 4599 ident: bib169 article-title: Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex publication-title: Biomaterials – volume: 63 start-page: 2645 year: 2003 end-page: 2648 ident: bib26 article-title: Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity publication-title: Canc. Res. – volume: 3 start-page: 597 year: 2004 end-page: 603 ident: bib51 article-title: Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen publication-title: Mol. Canc. Therapeut. – volume: 167 start-page: 111 year: 2017 end-page: 116 ident: bib121 article-title: A PSMA-targeted theranostic agent for photodynamic therapy publication-title: J. Photochem. Photobiol. B Biol. – volume: vol. 899 start-page: 489 year: 2012 end-page: 497 ident: bib89 article-title: Challenges in the development and manufacturing of antibody-drug conjugates publication-title: Ther. Proteins. Methods Mol. Biol. (Methods Protoc. – volume: 64 start-page: 4 year: 2021 end-page: 13 ident: bib142 article-title: Dual-labeled prostate-specific membrane antigen (PSMA)-targeting agent for preoperative molecular imaging and fluorescence-guided surgery for prostate cancer publication-title: J. Label. Compd. Radiopharm. – volume: 58 start-page: 4055 year: 1998 end-page: 4060 ident: bib68 article-title: Constitutive and antibody-induced internalization of prostate-specific membrane antigen publication-title: Canc. Res. – volume: 61 start-page: 735 year: 2020 end-page: 742 ident: bib160 article-title: Radiohybrid ligands: a novel tracer concept exemplified by 18 F- or 68 Ga-labeled rhPSMA inhibitors publication-title: J. Nucl. Med. – volume: 513 start-page: 138 year: 2016 end-page: 147 ident: bib50 article-title: Discovery of PSMA-specific peptide ligands for targeted drug delivery publication-title: Int. J. Pharm. – volume: 5 start-page: 1388 year: 2015 end-page: 1401 ident: bib79 article-title: PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status publication-title: Theranostics – volume: 59 start-page: 639 year: 2018 end-page: 645 ident: bib127 article-title: PSMA-11–Derived dual-Labeled PSMA inhibitors for preoperative PET imaging and precise fluorescence-Guided surgery of prostate cancer publication-title: J. Nucl. Med. – volume: 40 start-page: 1754 year: 2009 end-page: 1761 ident: bib16 article-title: Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers publication-title: Hum. Pathol. – volume: 5 start-page: 1 year: 2015 end-page: 13 ident: bib20 article-title: Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors publication-title: EJNMMI Res. – volume: 27 start-page: 1447 year: 2016 end-page: 1455 ident: bib38 article-title: Preclinical comparative study of 68Ga-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA publication-title: Bioconjugate Chem. – volume: 104 start-page: 932 year: 2007 end-page: 936 ident: bib52 article-title: Biomimetic amplification of nanoparticle homing to tumors publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 23 start-page: 2377 year: 2012 end-page: 2385 ident: bib140 article-title: Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen publication-title: Bioconjugate Chem. – volume: 15 start-page: 1 year: 2019 end-page: 15 ident: bib73 article-title: Sequential targeting TGF-β signaling and KRAS mutation increases therapeutic efficacy in pancreatic cancer publication-title: Small – volume: 15 start-page: 1834 year: 2016 end-page: 1844 ident: bib119 article-title: Theranostic agents for photodynamic therapy of prostate cancer by targeting prostate-specific membrane antigen publication-title: Mol. Canc. Therapeut. – volume: 314 start-page: 2201 year: 2017 end-page: 2207 ident: bib115 article-title: Preparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical publication-title: J. Radioanal. Nucl. Chem. – volume: 473 start-page: 347 year: 2016 end-page: 364 ident: bib141 article-title: New photosensitizers for photodynamic therapy publication-title: Biochem. J. – volume: 119 start-page: 902 year: 2019 end-page: 956 ident: bib148 article-title: Radioactive main group and rare Earth metals for imaging and therapy publication-title: Chem. Rev. – volume: 57 start-page: 2321 year: 1997 end-page: 2324 ident: bib11 article-title: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization publication-title: Canc. Res. – volume: 4 year: 2012 ident: bib78 article-title: Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile publication-title: Sci. Transl. Med. – volume: 98 start-page: 335 year: 2006 end-page: 344 ident: bib86 article-title: Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers publication-title: J. Natl. Cancer Inst. – volume: 24 start-page: 2340 year: 2014 end-page: 2345 ident: bib47 article-title: Structural characterization of P1′-diversified urea-based inhibitors of glutamate carboxypeptidase II publication-title: Bioorg. Med. Chem. Lett – volume: 21 start-page: 516 year: 2018 end-page: 523 ident: bib58 article-title: Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis publication-title: Prostate Cancer Prostatic Dis. – volume: 5 start-page: 323 year: 2017 end-page: 341 ident: bib149 article-title: Hybrid intraoperative imaging techniques in radioguided surgery: present clinical applications and future outlook publication-title: Clin. Transl. Imaging – volume: 12 start-page: 1 year: 2019 end-page: 9 ident: bib166 article-title: [ 177 Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography publication-title: Pharmaceuticals – volume: 120 start-page: 1290 year: 2014 end-page: 1314 ident: bib4 article-title: Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer publication-title: Cancer – volume: 117 start-page: 12133 year: 2017 end-page: 12164 ident: bib81 article-title: Ligand-targeted drug delivery publication-title: Chem. Rev. – volume: 333 start-page: 41 year: 2021 end-page: 64 ident: bib92 article-title: Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies publication-title: J. Contr. Release – volume: 28 start-page: 572 year: 2018 end-page: 576 ident: bib102 article-title: Synthesis of novel multivalent fluorescent inhibitors with high affinity to prostate cancer and their biological evaluation publication-title: Bioorg. Med. Chem. Lett – volume: 70 start-page: 7562 year: 2010 end-page: 7569 ident: bib177 article-title: Novel matrix metalloproteinase inhibitor [18F]marimastat- aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer publication-title: Canc. Res. – volume: 2014 year: 2014 ident: bib175 article-title: 18F-Labeled silicon-based fluoride acceptors: potential opportunities for novel positron emitting radiopharmaceuticals publication-title: BioMed Res. Int. – volume: 56 start-page: 140 year: 2015 end-page: 144 ident: bib70 article-title: Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? publication-title: J. Nucl. Med. – start-page: 4792 year: 2008 end-page: 4794 ident: bib138 article-title: Simplified syntheses of complex multifunctional nanomaterials publication-title: Chem. Commun. – volume: 72 start-page: 54 year: 2006 end-page: 61 ident: bib25 article-title: Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature publication-title: Microvasc. Res. – volume: 22 start-page: 1700 year: 2011 end-page: 1705 ident: bib124 article-title: Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody–indocyanine green (ICG) conjugate publication-title: Bioconjugate Chem. – volume: 22 start-page: 1403 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib125 article-title: Fluorescent image-guided surgery with an anti-Prostate Stem Cell Antigen (PSCA) diabody enables targeted resection of mouse prostate cancer xenografts in real time publication-title: Clin. Canc. Res. doi: 10.1158/1078-0432.CCR-15-0503 – volume: 13 start-page: 951 year: 2013 ident: 10.1016/j.ejmech.2021.113752_bib77 article-title: PET imaging in prostate cancer: focus on prostate-specific membrane antigen publication-title: Curr. Top. Med. Chem. doi: 10.2174/1568026611313080008 – volume: 68 start-page: 394 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib2 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA. Canc. J. Clin. doi: 10.3322/caac.21492 – volume: 55 start-page: 5922 year: 2012 ident: 10.1016/j.ejmech.2021.113752_bib33 article-title: Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds publication-title: J. Med. Chem. doi: 10.1021/jm300488m – volume: 57 start-page: 2321 year: 1997 ident: 10.1016/j.ejmech.2021.113752_bib11 article-title: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization publication-title: Canc. Res. – volume: 53 start-page: 4231 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib158 article-title: A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors publication-title: Angew. Chem. Int. Ed. doi: 10.1002/anie.201310709 – volume: 144 start-page: 1361 year: 2007 ident: 10.1016/j.ejmech.2021.113752_bib23 article-title: Expression of glutamate carboxypeptidase II in human brain publication-title: Neuroscience doi: 10.1016/j.neuroscience.2006.10.022 – volume: 20 start-page: 392 year: 2010 ident: 10.1016/j.ejmech.2021.113752_bib8 article-title: Bioisosterism of urea-based GCPII inhibitors: synthesis and structure–activity relationship studies publication-title: Bioorg. Med. Chem. Lett doi: 10.1016/j.bmcl.2009.10.061 – ident: 10.1016/j.ejmech.2021.113752_bib103 – volume: 52 start-page: 2747 year: 1992 ident: 10.1016/j.ejmech.2021.113752_bib88 article-title: Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the “binding site barrier publication-title: Canc. Res. – volume: 40 start-page: 1754 year: 2009 ident: 10.1016/j.ejmech.2021.113752_bib16 article-title: Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2009.06.003 – volume: 61 start-page: 735 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib160 article-title: Radiohybrid ligands: a novel tracer concept exemplified by 18 F- or 68 Ga-labeled rhPSMA inhibitors publication-title: J. Nucl. Med. doi: 10.2967/jnumed.119.234922 – year: 2006 ident: 10.1016/j.ejmech.2021.113752_bib174 – volume: 45 start-page: 8149 year: 2006 ident: 10.1016/j.ejmech.2021.113752_bib76 article-title: An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform publication-title: Angew. Chem. Int. Ed. doi: 10.1002/anie.200602251 – volume: 1 start-page: 16014 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib84 article-title: Analysis of nanoparticle delivery to tumours publication-title: Nat. Rev. Mater. doi: 10.1038/natrevmats.2016.14 – volume: 6 start-page: 1 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib165 article-title: Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors? publication-title: EJNMMI Radiopharm. Chem. doi: 10.1186/s41181-021-00124-1 – volume: 45 start-page: 6047 year: 2006 ident: 10.1016/j.ejmech.2021.113752_bib176 article-title: 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor publication-title: Angew. Chem. Int. Ed. doi: 10.1002/anie.200600795 – volume: 7 start-page: 927—935 year: 1987 ident: 10.1016/j.ejmech.2021.113752_bib9 article-title: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients publication-title: Anticancer Res. – volume: 59 start-page: 3192 year: 1999 ident: 10.1016/j.ejmech.2021.113752_bib13 article-title: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature publication-title: Canc. Res. – volume: 47 start-page: 493 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib150 article-title: Clinical applications of radiolabeled peptides for PET publication-title: Semin. Nucl. Med. doi: 10.1053/j.semnuclmed.2017.05.007 – volume: 117 start-page: 12133 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib81 article-title: Ligand-targeted drug delivery publication-title: Chem. Rev. doi: 10.1021/acs.chemrev.7b00013 – volume: 167 start-page: 111 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib121 article-title: A PSMA-targeted theranostic agent for photodynamic therapy publication-title: J. Photochem. Photobiol. B Biol. doi: 10.1016/j.jphotobiol.2016.12.018 – volume: 74 start-page: 659 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib109 article-title: Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer publication-title: Prostate doi: 10.1002/pros.22784 – volume: 17 start-page: 7645 year: 2011 ident: 10.1016/j.ejmech.2021.113752_bib161 article-title: 2-(3-{1-Carboxy-5-[(6-[ 18 F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic acid, [ 18 F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer publication-title: Clin. Canc. Res. doi: 10.1158/1078-0432.CCR-11-1357 – volume: 82 start-page: 2256 year: 1998 ident: 10.1016/j.ejmech.2021.113752_bib12 article-title: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S – volume: 120 start-page: 1290 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib4 article-title: Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer publication-title: Cancer doi: 10.1002/cncr.28509 – volume: 49 start-page: 2876 year: 2006 ident: 10.1016/j.ejmech.2021.113752_bib32 article-title: Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1′ side chain publication-title: J. Med. Chem. doi: 10.1021/jm051019l – volume: 53 start-page: 1611 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib56 article-title: PSMA-targeted contrast agents for intraoperative imaging of prostate cancer publication-title: Chem. Commun. doi: 10.1039/C6CC09781B – volume: 82 start-page: 309 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib64 article-title: Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: a state-of-the-art review publication-title: Drug Dev. Res. doi: 10.1002/ddr.21758 – volume: 98 start-page: 335 year: 2006 ident: 10.1016/j.ejmech.2021.113752_bib86 article-title: Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djj070 – volume: 473 start-page: 347 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib141 article-title: New photosensitizers for photodynamic therapy publication-title: Biochem. J. doi: 10.1042/BJ20150942 – volume: 21 start-page: 7513 year: 2011 ident: 10.1016/j.ejmech.2021.113752_bib151 article-title: Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates publication-title: Bioorg. Med. Chem. Lett doi: 10.1016/j.bmcl.2011.06.107 – volume: 48 start-page: 596 year: 2007 ident: 10.1016/j.ejmech.2021.113752_bib153 article-title: Indication for different mechanisms of kidney uptake of radiolabeled peptides publication-title: J. Nucl. Med. doi: 10.2967/jnumed.106.036020 – volume: 24 start-page: 2340 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib47 article-title: Structural characterization of P1′-diversified urea-based inhibitors of glutamate carboxypeptidase II publication-title: Bioorg. Med. Chem. Lett doi: 10.1016/j.bmcl.2014.03.066 – volume: 130 start-page: 1 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib135 article-title: The impact of 68Ga-PSMA PET/CT and PET/MRI on the management of prostate cancer publication-title: Urology doi: 10.1016/j.urology.2019.04.004 – volume: 57 start-page: 3629 year: 1997 ident: 10.1016/j.ejmech.2021.113752_bib14 article-title: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium publication-title: Canc. Res. – ident: 10.1016/j.ejmech.2021.113752_bib100 – volume: 43 start-page: 1857 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib155 article-title: Fluorescence guided surgery and tracer-dose, fact or fiction? publication-title: Eur. J. Nucl. Med. Mol. Imag. doi: 10.1007/s00259-016-3372-y – ident: 10.1016/j.ejmech.2021.113752_bib97 – volume: 65 start-page: 564 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib172 article-title: Janus γ-Fe2O3/SiO2-based nanotheranostics for dual-modal imaging and enhanced synergistic cancer starvation/chemodynamic therapy publication-title: Sci. Bull. doi: 10.1016/j.scib.2019.12.024 – volume: 4 year: 2012 ident: 10.1016/j.ejmech.2021.113752_bib78 article-title: Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3003651 – volume: 8 start-page: 2161 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib152 article-title: Tumor-targeted dual-modality imaging to improve intraoperative visualization of clear cell renal cell carcinoma: a first in man study publication-title: Theranostics doi: 10.7150/thno.23335 – volume: 53 start-page: 227 year: 1993 ident: 10.1016/j.ejmech.2021.113752_bib10 article-title: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen publication-title: Canc. Res. – volume: 102 start-page: 5981 year: 2005 ident: 10.1016/j.ejmech.2021.113752_bib27 article-title: Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0502101102 – volume: 104 start-page: 932 year: 2007 ident: 10.1016/j.ejmech.2021.113752_bib52 article-title: Biomimetic amplification of nanoparticle homing to tumors publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0610298104 – volume: 9 start-page: 6824 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib69 article-title: PSMA-targeting agents for radio- and fluorescenceguided prostate cancer surgery publication-title: Theranostics doi: 10.7150/thno.36739 – volume: 25 start-page: 5784 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib159 article-title: Polypeptide-based molecular platform and its docetaxel/sulfo-cy5-containing conjugate for targeted delivery to prostate specific membrane antigen publication-title: Molecules doi: 10.3390/molecules25245784 – volume: 22 start-page: 1879 year: 2011 ident: 10.1016/j.ejmech.2021.113752_bib60 article-title: Theranostics: combining imaging and therapy publication-title: Bioconjugate Chem. doi: 10.1021/bc200151q – volume: 59 start-page: 206 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib37 article-title: Fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.5b01268 – volume: 14 start-page: 1449 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib133 article-title: A fluorescent, [18F]-Positron-Emitting agent for imaging prostate-specific membrane antigen allows genetic reporting in adoptively transferred, genetically modified cells publication-title: ACS Chem. Biol. doi: 10.1021/acschembio.9b00160 – volume: 63 start-page: 2645 year: 2003 ident: 10.1016/j.ejmech.2021.113752_bib26 article-title: Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity publication-title: Canc. Res. – volume: 60 start-page: 736 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib157 article-title: Proceedings: pathways for successful translation of new imaging agents and modalities—phase III studies publication-title: J. Nucl. Med. doi: 10.2967/jnumed.118.219824 – volume: 6 start-page: 1802070 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib74 article-title: Therapeutic remodeling of the tumor microenvironment enhances nanoparticle delivery publication-title: Adv. Sci. doi: 10.1002/advs.201802070 – volume: 2014 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib175 article-title: 18F-Labeled silicon-based fluoride acceptors: potential opportunities for novel positron emitting radiopharmaceuticals publication-title: BioMed Res. Int. doi: 10.1155/2014/454503 – volume: 12 start-page: 4969 year: 2004 ident: 10.1016/j.ejmech.2021.113752_bib30 article-title: Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2004.06.031 – volume: 64 start-page: 2151 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib107 article-title: Development of heterobivalent theranostic probes having high affinity/selectivity for the GRPR/PSMA publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c01785 – volume: 363 start-page: 1812 year: 2010 ident: 10.1016/j.ejmech.2021.113752_bib83 article-title: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1002965 – volume: 5 start-page: 1 year: 2015 ident: 10.1016/j.ejmech.2021.113752_bib20 article-title: Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors publication-title: EJNMMI Res. doi: 10.1186/s13550-015-0104-4 – volume: 22 start-page: 523 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib65 article-title: Metal-based PSMA radioligands publication-title: Molecules doi: 10.3390/molecules22040523 – volume: 5 start-page: 1388 year: 2015 ident: 10.1016/j.ejmech.2021.113752_bib79 article-title: PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status publication-title: Theranostics doi: 10.7150/thno.13348 – start-page: 4792 year: 2008 ident: 10.1016/j.ejmech.2021.113752_bib138 article-title: Simplified syntheses of complex multifunctional nanomaterials publication-title: Chem. Commun. doi: 10.1039/b809537j – volume: 119 start-page: 902 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib148 article-title: Radioactive main group and rare Earth metals for imaging and therapy publication-title: Chem. Rev. doi: 10.1021/acs.chemrev.8b00294 – volume: 41 start-page: 355 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib106 article-title: Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer publication-title: Nucl. Med. Biol. doi: 10.1016/j.nucmedbio.2014.01.001 – volume: 12 start-page: 1 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib166 article-title: [ 177 Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography publication-title: Pharmaceuticals doi: 10.3390/ph12010018 – volume: 119 start-page: 870 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib147 article-title: Radioactive transition metals for imaging and therapy publication-title: Chem. Rev. doi: 10.1021/acs.chemrev.8b00281 – volume: 23 start-page: 688 year: 2012 ident: 10.1016/j.ejmech.2021.113752_bib39 article-title: 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging publication-title: Bioconjugate Chem. doi: 10.1021/bc200279b – volume: 56 start-page: 914 year: 2015 ident: 10.1016/j.ejmech.2021.113752_bib43 article-title: Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer publication-title: J. Nucl. Med. doi: 10.2967/jnumed.114.147413 – volume: 30 start-page: 76 year: 2012 ident: 10.1016/j.ejmech.2021.113752_bib90 article-title: Consideration for the safe and effective manufacturing of antibody drug conjugates publication-title: Chim. Oggi/Chemistry Today. – volume: 9 start-page: 421 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib98 article-title: Tumor uptake of triazine dendrimers decorated with four, sixteen, and sixty-four PSMA-targeted ligands: passive versus active tumor targeting publication-title: Biomolecules doi: 10.3390/biom9090421 – volume: 10 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib163 article-title: Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics publication-title: EJNMMI Res. doi: 10.1186/s13550-020-00740-z – volume: 60 start-page: 459 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib134 article-title: New developments in dual-labeled molecular imaging agents publication-title: J. Nucl. Med. doi: 10.2967/jnumed.118.213488 – volume: 119 start-page: 209 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib46 article-title: Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer publication-title: BJU Int. doi: 10.1111/bju.13540 – year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib139 – volume: 77 start-page: 542 year: 1999 ident: 10.1016/j.ejmech.2021.113752_bib87 article-title: Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations publication-title: Biophys. J. doi: 10.1016/S0006-3495(99)76911-0 – volume: 27 start-page: 379 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib96 article-title: Multivalent probes in molecular imaging: reality or future? publication-title: Trends Mol. Med. doi: 10.1016/j.molmed.2020.12.006 – volume: 7 start-page: 1 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib72 article-title: Nanotheranostics targeting the tumor microenvironment publication-title: Front. Bioeng. Biotechnol. doi: 10.3389/fbioe.2019.00197 – volume: 14 start-page: 2665 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib126 article-title: Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer publication-title: Beilstein J. Org. Chem. doi: 10.3762/bjoc.14.244 – volume: 6 start-page: 986 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib61 article-title: Versatile nanosystem-based cancer theranostics: design inspiration and predetermined routing publication-title: Theranostics doi: 10.7150/thno.14860 – volume: 58 start-page: 235 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib145 article-title: Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer publication-title: J. Nucl. Med. doi: 10.2967/jnumed.116.178939 – volume: 24 start-page: 1521 year: 2011 ident: 10.1016/j.ejmech.2021.113752_bib19 article-title: Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature publication-title: Mod. Pathol. doi: 10.1038/modpathol.2011.112 – volume: 35 start-page: 755 year: 1989 ident: 10.1016/j.ejmech.2021.113752_bib82 article-title: Current concepts in proteinuria publication-title: Clin. Chem. doi: 10.1093/clinchem/35.5.755 – volume: 63 start-page: 539 year: 2011 ident: 10.1016/j.ejmech.2021.113752_bib154 article-title: Approaches using molecular imaging technology - use of PET in clinical microdose studies publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2010.09.011 – volume: 246 start-page: 734 year: 2008 ident: 10.1016/j.ejmech.2021.113752_bib156 article-title: Imaging of lymph flow in breast cancer patients after microdose administration of a Methods : feasibility study publication-title: Radiology doi: 10.1148/radiol.2463070962 – volume: 44 start-page: 298 year: 2001 ident: 10.1016/j.ejmech.2021.113752_bib35 article-title: Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) publication-title: J. Med. Chem. doi: 10.1021/jm000406m – volume: 44 start-page: 4170 year: 2001 ident: 10.1016/j.ejmech.2021.113752_bib29 article-title: Design and Pharmacological Activity of Phosphinic Acid Based NAALADase publication-title: Inhibitors – volume: 14 start-page: 2585 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib93 article-title: Nanomaterials for nanotheranostics: tuning their properties according to disease needs publication-title: ACS Nano doi: 10.1021/acsnano.9b08133 – volume: 8 start-page: 1588 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib66 article-title: Prostate-specific membrane antigen (PSMA)-Targeted radionuclide probes for imaging and therapy of prostate cancer publication-title: Asian J. Org. Chem. doi: 10.1002/ajoc.201900329 – volume: 70 start-page: 7562 year: 2010 ident: 10.1016/j.ejmech.2021.113752_bib177 article-title: Novel matrix metalloproteinase inhibitor [18F]marimastat- aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer publication-title: Canc. Res. doi: 10.1158/0008-5472.CAN-10-1584 – volume: 6 start-page: 1619 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib44 article-title: 68Ga-HBED-CC-PSMA PET/CT versus histopathology in primary localized prostate cancer: a voxel-wise comparison publication-title: Theranostics doi: 10.7150/thno.15344 – start-page: 1 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib143 article-title: Small molecule, multimodal, [18F]-PET and fluorescence imaging agent targeting prostate-specific membrane antigen: first-in-human study publication-title: Clin. Genitourin. Canc. – volume: 59 start-page: 639 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib127 article-title: PSMA-11–Derived dual-Labeled PSMA inhibitors for preoperative PET imaging and precise fluorescence-Guided surgery of prostate cancer publication-title: J. Nucl. Med. doi: 10.2967/jnumed.117.201293 – volume: 13 start-page: 1 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib95 article-title: Current state of radiolabeled heterobivalent peptidic ligands in tumor imaging and therapy publication-title: Pharmaceuticals doi: 10.3390/ph13080173 – volume: 24 start-page: 679 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib28 article-title: Small-molecule PSMA ligands. Current state, SAR and perspectives publication-title: J. Drug Target. doi: 10.3109/1061186X.2016.1154564 – volume: 69 start-page: 6932 year: 2009 ident: 10.1016/j.ejmech.2021.113752_bib71 article-title: Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer publication-title: Canc. Res. doi: 10.1158/0008-5472.CAN-09-1682 – volume: 15 start-page: 1 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib73 article-title: Sequential targeting TGF-β signaling and KRAS mutation increases therapeutic efficacy in pancreatic cancer publication-title: Small doi: 10.1002/smll.201900631 – volume: 333 start-page: 41 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib92 article-title: Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies publication-title: J. Contr. Release doi: 10.1016/j.jconrel.2021.01.010 – volume: 30 start-page: 126894 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib48 article-title: Design and synthesis of a novel BODIPY-labeled PSMA inhibitor publication-title: Bioorg. Med. Chem. Lett doi: 10.1016/j.bmcl.2019.126894 – volume: 45 start-page: 860 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib21 article-title: Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives publication-title: Eur. J. Nucl. Med. Mol. Imag. doi: 10.1007/s00259-017-3922-y – volume: 17 start-page: 1 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib1 article-title: PSMA theranostics: current status and future directions publication-title: Mol. Imag. doi: 10.1177/1536012118776068 – volume: 74 start-page: 702 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib40 article-title: Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker publication-title: Prostate doi: 10.1002/pros.22789 – volume: 29 start-page: 3746 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib120 article-title: Tuning pharmacokinetics to improve tumor accumulation of a prostate-specific membrane antigen-targeted phototheranostic agent publication-title: Bioconjugate Chem. doi: 10.1021/acs.bioconjchem.8b00636 – volume: 56 start-page: 1169 year: 2015 ident: 10.1016/j.ejmech.2021.113752_bib54 article-title: 68 Ga- and 177 Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies publication-title: J. Nucl. Med. doi: 10.2967/jnumed.115.158550 – volume: 30 start-page: 1314 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib113 article-title: Development of bispecific NT-PSMA heterodimer for prostate cancer imaging: a potential approach to address tumor heterogeneity publication-title: Bioconjugate Chem. doi: 10.1021/acs.bioconjchem.9b00252 – volume: 33 start-page: 5053 year: 2013 ident: 10.1016/j.ejmech.2021.113752_bib173 article-title: Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy publication-title: Oncogene doi: 10.1038/onc.2013.497 – volume: 58 start-page: 4055 year: 1998 ident: 10.1016/j.ejmech.2021.113752_bib68 article-title: Constitutive and antibody-induced internalization of prostate-specific membrane antigen publication-title: Canc. Res. – volume: 16 start-page: 747 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib144 article-title: Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation publication-title: Mol. Imag. Biol. doi: 10.1007/s11307-014-0747-y – volume: 56 start-page: 140 year: 2015 ident: 10.1016/j.ejmech.2021.113752_bib70 article-title: Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies? publication-title: J. Nucl. Med. doi: 10.2967/jnumed.114.149526 – volume: 64 start-page: 4 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib142 article-title: Dual-labeled prostate-specific membrane antigen (PSMA)-targeting agent for preoperative molecular imaging and fluorescence-guided surgery for prostate cancer publication-title: J. Label. Compd. Radiopharm. doi: 10.1002/jlcr.3884 – volume: 59 start-page: 1761 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib41 article-title: Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-Targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.5b01210 – volume: 70 start-page: 385 year: 2007 ident: 10.1016/j.ejmech.2021.113752_bib15 article-title: Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms publication-title: Urology doi: 10.1016/j.urology.2007.03.025 – volume: 70 start-page: 926 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib45 article-title: Sensitivity, specificity, and predictors of positive 68Ga–Prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis publication-title: Eur. Urol. doi: 10.1016/j.eururo.2016.06.021 – volume: 143 start-page: 37 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib75 article-title: Intratumoral fate of functional nanoparticles in response to microenvironment factor: implications on cancer diagnosis and therapy publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2019.06.007 – volume: 118 start-page: 208 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib112 article-title: Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2016.04.033 – volume: 10 start-page: 1 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib171 article-title: Docetaxel and doxorubicin codelivery by nanocarriers for synergistic treatment of prostate cancer publication-title: Front. Pharmacol. doi: 10.3389/fphar.2019.01436 – volume: 12 start-page: 1 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib108 article-title: Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer—optimization of the affinity towards PSMA by linker modification in murine model publication-title: Pharmaceutics doi: 10.3390/pharmaceutics12070614 – volume: 27 start-page: 1447 issue: 6 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib38 article-title: Preclinical comparative study of 68Ga-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA publication-title: Bioconjugate Chem. doi: 10.1021/acs.bioconjchem.5b00679 – volume: 8 start-page: 1588 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib116 article-title: Prostate-specific membrane antigen (PSMA)-Targeted radionuclide probes for imaging and therapy of prostate cancer publication-title: Asian J. Org. Chem. doi: 10.1002/ajoc.201900329 – volume: 15 start-page: 1834 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib119 article-title: Theranostic agents for photodynamic therapy of prostate cancer by targeting prostate-specific membrane antigen publication-title: Mol. Canc. Therapeut. doi: 10.1158/1535-7163.MCT-15-0722 – start-page: 1 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib118 article-title: A structure-activity relationship study of bimodal BODIPY-labeled PSMA-targeting bioconjugates publication-title: ChemMedChem – volume: 58 start-page: 17S year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib80 article-title: Glu-ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers publication-title: J. Nucl. Med. doi: 10.2967/jnumed.116.186775 – volume: 12 start-page: 10 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib6 article-title: Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer publication-title: Cureus – volume: 5 start-page: 323 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib149 article-title: Hybrid intraoperative imaging techniques in radioguided surgery: present clinical applications and future outlook publication-title: Clin. Transl. Imaging doi: 10.1007/s40336-017-0235-x – volume: 21 start-page: 516 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib58 article-title: Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis publication-title: Prostate Cancer Prostatic Dis. doi: 10.1038/s41391-018-0055-8 – volume: 58 start-page: 1624 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib167 article-title: Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding publication-title: J. Nucl. Med. doi: 10.2967/jnumed.117.191395 – volume: 28 start-page: 572 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib102 article-title: Synthesis of novel multivalent fluorescent inhibitors with high affinity to prostate cancer and their biological evaluation publication-title: Bioorg. Med. Chem. Lett doi: 10.1016/j.bmcl.2018.01.047 – volume: 57 start-page: 243 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib34 article-title: δ-thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors publication-title: J. Med. Chem. doi: 10.1021/jm401703a – volume: 25 start-page: 393 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib114 article-title: Heterobivalent agents targeting PSMA and integrin - αvβ3 publication-title: Bioconjugate Chem. doi: 10.1021/bc4005377 – year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib111 article-title: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR publication-title: OncoImmunology doi: 10.1080/2162402X.2019.1659095 – volume: 71 start-page: 630 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib5 article-title: EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer publication-title: Eur. Urol. doi: 10.1016/j.eururo.2016.08.002 – ident: 10.1016/j.ejmech.2021.113752_bib132 – volume: 31 start-page: 4592 year: 2010 ident: 10.1016/j.ejmech.2021.113752_bib169 article-title: Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex publication-title: Biomaterials doi: 10.1016/j.biomaterials.2010.02.030 – volume: 14 start-page: 1 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib18 article-title: Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases publication-title: Canc. Cell Int. – volume: 46 start-page: 1989 year: 2003 ident: 10.1016/j.ejmech.2021.113752_bib31 article-title: Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor publication-title: J. Med. Chem. doi: 10.1021/jm020515w – volume: 107 start-page: 1150 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib59 article-title: Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells publication-title: J. Biomed. Mater. Res. B Appl. Biomater. doi: 10.1002/jbm.b.34208 – volume: 31 start-page: 1199 year: 2007 ident: 10.1016/j.ejmech.2021.113752_bib24 article-title: Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2 publication-title: Int. J. Oncol. – volume: 13 start-page: 2595 year: 2014 ident: 10.1016/j.ejmech.2021.113752_bib55 article-title: Development of targeted near-infrared imaging agents for prostate cancer publication-title: Mol. Canc. Therapeut. doi: 10.1158/1535-7163.MCT-14-0422 – volume: 61 start-page: 6 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib122 article-title: Prostate-specific membrane antigen–guided surgery publication-title: J. Nucl. Med. doi: 10.2967/jnumed.119.232330 – volume: 60 start-page: 71 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib130 article-title: Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer publication-title: J. Nucl. Med. doi: 10.2967/jnumed.118.212720 – volume: 62 start-page: 679 year: 2021 ident: 10.1016/j.ejmech.2021.113752_bib164 article-title: Safety, biodistribution, and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers publication-title: J. Nucl. Med. doi: 10.2967/jnumed.120.252114 – volume: 27 start-page: 737 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib104 article-title: Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer publication-title: Bioconjugate Chem. doi: 10.1021/acs.bioconjchem.5b00687 – volume: 3 start-page: 597 year: 2004 ident: 10.1016/j.ejmech.2021.113752_bib51 article-title: Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen publication-title: Mol. Canc. Therapeut. doi: 10.1158/1535-7163.597.3.5 – volume: 17 start-page: 561 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib85 article-title: Linkers having a crucial role in antibody–drug conjugates publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms17040561 – volume: 58 start-page: 8751 year: 2015 ident: 10.1016/j.ejmech.2021.113752_bib91 article-title: Antibody–drug conjugates and small molecule–drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.5b00457 – volume: 40 start-page: 278 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib110 article-title: Synthesis and preclinical evaluation of the 177 Lu-DOTA-PSMA(inhibitor)-Lys 3 -bombesin heterodimer designed as a radiotheranostic probe for prostate cancer publication-title: Nucl. Med. Commun. doi: 10.1097/MNM.0000000000000966 – volume: 513 start-page: 138 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib50 article-title: Discovery of PSMA-specific peptide ligands for targeted drug delivery publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2016.08.048 – volume: 10 start-page: 1678 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib53 article-title: Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity publication-title: Theranostics doi: 10.7150/thno.40482 – volume: 39 start-page: 40 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib7 article-title: Targeting prostate cancer: prostate-specific membrane antigen based diagnosis and therapy publication-title: Med. Res. Rev. doi: 10.1002/med.21508 – volume: 61 start-page: 234 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib129 article-title: Hybrid tracers based on cyanine backbones targeting prostate-specific membrane antigen: tuning pharmacokinetic properties and exploring dye-protein interaction publication-title: J. Nucl. Med. doi: 10.2967/jnumed.119.233064 – volume: 14 start-page: 1407 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib170 article-title: Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA) publication-title: Nanomed. Nanotechnol. Biol. Med. doi: 10.1016/j.nano.2018.04.011 – volume: 58 start-page: 67S year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib123 article-title: Prostate-specific membrane antigen ligands for imaging and therapy publication-title: J. Nucl. Med. doi: 10.2967/jnumed.116.186767 – volume: 50 start-page: 9167 year: 2011 ident: 10.1016/j.ejmech.2021.113752_bib128 article-title: Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen publication-title: Angew. Chem. Int. Ed. doi: 10.1002/anie.201102872 – volume: 130 start-page: 42 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib117 article-title: PSMA ligands in prostate cancer – probe optimization and theranostic applications publication-title: Methods doi: 10.1016/j.ymeth.2017.06.026 – volume: 58 start-page: 425 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib162 article-title: Preclinical evaluation of 18 F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging publication-title: J. Nucl. Med. doi: 10.2967/jnumed.116.181768 – volume: 390 start-page: 624 year: 2009 ident: 10.1016/j.ejmech.2021.113752_bib42 article-title: A low molecular weight PSMA-based fluorescent imaging agent for cancer publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2009.10.017 – volume: 31 start-page: 375 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib137 article-title: Image-guided surgery: are we getting the most out of small-molecule prostate-specific-membrane-antigen-targeted tracers? publication-title: Bioconjugate Chem. doi: 10.1021/acs.bioconjchem.9b00758 – volume: 3 start-page: 81 year: 1997 ident: 10.1016/j.ejmech.2021.113752_bib22 article-title: Prostate-specific membrane antigen expression in normal and malignant human tissues publication-title: Clin. Canc. Res. – volume: 3 start-page: 1 year: 2013 ident: 10.1016/j.ejmech.2021.113752_bib178 article-title: Radiofluorination using aluminum-fluoride (Al18F) publication-title: EJNMMI Res. doi: 10.1186/2191-219X-3-36 – volume: 22 start-page: 1700 year: 2011 ident: 10.1016/j.ejmech.2021.113752_bib124 article-title: Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody–indocyanine green (ICG) conjugate publication-title: Bioconjugate Chem. doi: 10.1021/bc2002715 – volume: 207 start-page: 266 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib136 article-title: Dual PET and near-infrared fluorescence imaging probes as tools for imaging in oncology publication-title: Am. J. Roentgenol. doi: 10.2214/AJR.16.16181 – volume: 49 start-page: 302 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib67 article-title: PSMA-targeted radiopharmaceuticals for imaging and therapy publication-title: Semin. Nucl. Med. doi: 10.1053/j.semnuclmed.2019.02.008 – volume: 19 start-page: 93 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib146 article-title: Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy publication-title: Nucl. Med. Rev. Cent. E Eur. doi: 10.5603/NMR.2016.0019 – volume: 21 start-page: 943 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib168 article-title: Toward 18 F-labeled theranostics: a single agent that can Be labeled with 18 F, 64 Cu, or 177 Lu publication-title: Chembiochem doi: 10.1002/cbic.201900632 – volume: 322 start-page: 237 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib63 article-title: Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer publication-title: J. Radioanal. Nucl. Chem. doi: 10.1007/s10967-019-06800-6 – volume: 2 start-page: 1 year: 2012 ident: 10.1016/j.ejmech.2021.113752_bib101 article-title: A dimerized urea-based inhibitor of the prostatespecific membrane antigen for 68Ga-PET imaging of prostate cancer publication-title: EJNMMI Res. doi: 10.1186/2191-219X-2-23 – volume: 11 start-page: 358 year: 2019 ident: 10.1016/j.ejmech.2021.113752_bib105 article-title: Synthesis and preclinical evaluation of radio-iodinated GRPR/PSMA bispecific heterodimers for the theranostics application in prostate cancer publication-title: Pharmaceutics doi: 10.3390/pharmaceutics11070358 – volume: 135 start-page: 1486 year: 2011 ident: 10.1016/j.ejmech.2021.113752_bib17 article-title: Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme publication-title: Arch. Pathol. Lab Med. doi: 10.5858/arpa.2010-0740-OA – volume: 72 start-page: 54 year: 2006 ident: 10.1016/j.ejmech.2021.113752_bib25 article-title: Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature publication-title: Microvasc. Res. doi: 10.1016/j.mvr.2006.03.004 – volume: 314 start-page: 2201 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib115 article-title: Preparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical publication-title: J. Radioanal. Nucl. Chem. doi: 10.1007/s10967-017-5555-9 – volume: 61 start-page: 4256 year: 2018 ident: 10.1016/j.ejmech.2021.113752_bib131 article-title: 18F-Positron emitting/trimethine cyanine-fluorescent contrast for image-guided prostate cancer management publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.8b00240 – volume: 71 start-page: 618 year: 2017 ident: 10.1016/j.ejmech.2021.113752_bib3 article-title: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent publication-title: Eur. Urol. doi: 10.1016/j.eururo.2016.08.003 – volume: vol. 899 start-page: 489 year: 2012 ident: 10.1016/j.ejmech.2021.113752_bib89 article-title: Challenges in the development and manufacturing of antibody-drug conjugates – volume: 8 start-page: 1 year: 2013 ident: 10.1016/j.ejmech.2021.113752_bib49 article-title: Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA) publication-title: PloS One – volume: 23 start-page: 2377 issue: 12 year: 2012 ident: 10.1016/j.ejmech.2021.113752_bib140 article-title: Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen publication-title: Bioconjugate Chem. doi: 10.1021/bc3003919 – volume: 27 start-page: 1681 year: 2016 ident: 10.1016/j.ejmech.2021.113752_bib57 article-title: Design of a small-molecule drug conjugate for prostate cancer targeted theranostics publication-title: Bioconjugate Chem. doi: 10.1021/acs.bioconjchem.6b00222 – volume: 63 start-page: 9258 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib99 article-title: Bivalent inhibitors of prostate-specific membrane antigen conjugated to desferrioxamine B squaramide labeled with zirconium-89 or gallium-68 for diagnostic imaging of prostate cancer publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c00291 – volume: 51 start-page: 7737 year: 2008 ident: 10.1016/j.ejmech.2021.113752_bib36 article-title: Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization publication-title: J. Med. Chem. doi: 10.1021/jm800765e – volume: 12 start-page: 1 year: 2020 ident: 10.1016/j.ejmech.2021.113752_bib62 article-title: PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy publication-title: Cancers doi: 10.3390/cancers12061367 |
| SSID | ssj0005600 |
| Score | 2.4178305 |
| SecondaryResourceType | review_article |
| Snippet | This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 113752 |
| SubjectTerms | Anticancer drugs Antigens, Surface - chemistry Antigens, Surface - metabolism Antineoplastic Combined Chemotherapy Protocols - chemistry Antineoplastic Combined Chemotherapy Protocols - pharmacology Cancer diagnosis Cytostatic Agents - chemistry Cytostatic Agents - pharmacology Double conjugates Glutamate Carboxypeptidase II - antagonists & inhibitors Glutamate Carboxypeptidase II - chemistry Glutamate Carboxypeptidase II - metabolism Humans Male Molecular Structure Molecular Weight Prostate cancer Prostatic Neoplasms - diagnosis Prostatic Neoplasms - drug therapy PSMA Targeted delivery |
| Title | PSMA-targeted low-molecular double conjugates for diagnostics and therapy |
| URI | https://dx.doi.org/10.1016/j.ejmech.2021.113752 https://www.ncbi.nlm.nih.gov/pubmed/34464875 https://www.proquest.com/docview/2568250127 |
| Volume | 225 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEB5ED3oR39YXK4gn16ab3aw9lqJURSmo4G3JZidgqanYFunF3-5sNvFxEMFjQjZZdoaZ78u8AI7iPCMn13KcGApyic7yM5Qxj7JEtZ0WqGNfO3xzm_Qe5NWjepyDbl0L49MqK9sfbHppras7zeo0my9PT8078j6EHmJJpMU3FfF2WErttfz0_VuaRxLKUOhhT7pkXT5X5njh4BnLkIRo-eEmWonf3NNv8LN0QxcrsFzhR9YJW1yFOSzWYLFbj21bg-N-aEY9O2H3X7VV4xN2zPpfbapn63DZv7vp8JAJjo4NR2_8uZ6Vy9xoaofIiCwPpv5H25gRuGUu5OX597G0cCwUb8024OHi_L7b49VgBZ6Rv5rwnDALqlRlLiE8prTzXcciVInMBYmL-DIKZbNU68gq4UQ7T6xLM5dHebuM7W3CfDEqcBtYGpEOtC2hPp1KKbS1kZUC40S1ziKHsgFxfZ4mq7qO--EXQ1Onlw1MkILxUjBBCg3gn6teQteNP57XtajMD-0x5Bj-WHlYS9aQoHy0JC1wNB0bwoLEnn1kvgFbQeSfe4mJRHumt_Pv7-7Ckr8qE2PUHsxPXqe4T_BmYg9K_T2Ahc7lde_2Axdh-II |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB4hOMAFsTzLLrtGQpwwTR07pkdUgcqjqBJF4mbF8URqVVJEW6164bczjhNgDwhpr4mdWP6cmW8yL4CjOM9IybUcJwsFuURn-RnKmEdZotpOC9Sxzx3u3SXdB3n9qB6XoFPnwviwykr2B5leSuvqSrPazebzcNi8J-1D7CGWZLT4oiIkh1ckfb6-jcHp66c4jyTkodBob3XJOn-uDPLC0ROWPgnR8t1NtBJf6aev-Gephy43YL0ikOw8rPEHLGGxCaudum_bJhz3QzXqxQkbfCRXTU_YMet_1KlebMFV_753zkMoODo2nvzlT3WzXOYmcztGRtbyaO7_tE0ZsVvmQmCefx5LC8dC9tZiGx4uLwadLq86K_CMFNaM50RaUKUqcwkRMqWdLzsWoUpkLggvMphRKJulWkdWCSfaeWJdmrk8ytulc28HlotJgXvA0ogOQdsS7dOplEJbG1kpME5U6yxyKBsQ1_tpsqrsuO9-MTZ1fNnIBBSMR8EEFBrA32c9h7Ib34zXNVTmn-NjSDN8M_OwRtYQUN5dkhY4mU8NkUEyn71rvgG7AfL3tcRkRXtTb_-_3_sHVruD3q25vbq7-Qlr_k4ZJaN-wfLsZY4HxHVm9nd5lt8AwFr6EA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PSMA-targeted+low-molecular+double+conjugates+for+diagnostics+and+therapy&rft.jtitle=European+journal+of+medicinal+chemistry&rft.au=Petrov%2C+Stanislav+A&rft.au=Zyk%2C+Nikolay+Y&rft.au=Machulkin%2C+Aleksei+E&rft.au=Beloglazkina%2C+Elena+K&rft.date=2021-12-05&rft.eissn=1768-3254&rft.volume=225&rft.spage=113752&rft_id=info:doi/10.1016%2Fj.ejmech.2021.113752&rft_id=info%3Apmid%2F34464875&rft.externalDocID=34464875 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0223-5234&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0223-5234&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0223-5234&client=summon |